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In order address the potential long term prospect of gene therapy for some mitochondrial 
based diseases, it has been suggested that one would be to manipulate the mitochondrial 
DNA (mtDNA) in vitro, so as to alter mutations prior to introducing the repaired 
mitochondrial genome into somatic or germ cells . Moreover, the creation of 
heteroplasmic mice in this way would provide a greater understanding of the dynamics of 
mitochondria in mitochondrial diseases. Mitochondrial isolation and transfer techniques 
would therefore be of great importance in the production of appropriate mice models in 
generating mitochondrial disease based therapies.  
 
In this thesis we report the successful introduction and detection of foreign mtDNA into 
embryos, while providing a detailed, efficient and replicable methodology which can be 
used to further study the production of appropriate mice models in the study of 
mitochondrial diseases.  
 
To do so, we first discuss detailed methodology to study the morphological changes in 
the preimplanted embryos and additionally, for the selection of viable embryos showing 
good development and a high percentage success rate of development to the blastocyst 
stage in vitro. This will be crucial in selecting embryos for micromanipulation and also 
implantation into pseudo-pregnant females in creating mouse models. 
 
It has been reported that mitochondria play a vital role in the metabolism of energy 






preimplantation embryo development. However, the role of mitochondria during 
fertilization and cleavage stages of embryo development is not yet fully understood. 
Here, we provide a detailed methodology for studying the mitochondrial distribution and 
relocation in embryos at the various stages of development in vitro.  
 
In another study, to create heterogeneous embryos using two related sub-strains of the 
Mus Musculus Domesticus species, the detection of the successful transfer of 
mitochondria was performed using the sequence differences in the COIII polymorphic 
site to distinguish between the two mice sub-strains used. The COIII polymorphism is 
situated at the 9348bp site of the mtDNA sequence and has been shown to be present 
exclusively in the C57BL/6J mtDNA but not in the BALB/cJ, thus being able to 
differentiate between the two sub strains mtDNA’s and confirm the successful transfer of 
the ‘foreign’ mitochondria.  
  
In previously reported experiments, one of the problematic areas in detecting the 
successful transfer was to isolate the mitochondria from individual embryos followed by 
their mtDNA isolation. However this protocol was reported by the author to be tedious 
and many difficulties were faced in the attempt to isolate the mitochondrial DNA from 
single embryos. Therefore, in our experiment, we use an alternative simple methodology 
to avoid these complications and improve the efficiency while successfully detecting and 







We provide methodology to study the fate of the injected and native mitochondria in the 
embryos generated. Furthermore, we attempt to determine a concentration ratio between 
the native and foreign mitochondria in the embryos. This will help us understand whether 
the injected or native mitochondria are decreasing in concentrations or appear to be 
deleted or diluted out during sequential cleavage of the embryos as a defense mechanism 
to the foreign mitochondria. This is an  interesting area to study as it has been reported 
that the few sperm mitochondria that enter the oocyte at fertilization appear to be 
degraded or diluted out during embryonic development and cannot be detected at the 
blastocyst stages.  
 
This thesis has provided detailed and reproducible methodology which serve as good 
initial steps for the production of appropriate mouse models in the future study of 
mitochondrial diseases. These mouse models could in turn help us further our knowledge 
in the field of mitochondrial medicine and assist us in gaining a better understanding of 
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Mitochondrial DNA: DNA specific to the mitochondrion 
 
Hetero-: Combining form from the Greek heteros meaning different. 
 
Heterogeneous: Composed of varied cell types. In this thesis, heterogeneous refers to 
composition of two different mtDNA types. 
 
Micromanipulation: A mechanical device for making small movements in order to 
manipulate or treat a microscopic object with a fine needle, small forceps, micropipette or 
other very small tools.     
 
PCR: The first practical system for in vitro amplification of DNA and as such one of the 
most important recent developments in molecular biology. 
 
Nested PCR: A second PCR is performed on the product of an earlier PCR using primers 
which are internal to the originals. This improves sensitivity without impairing specificity. 
 
Primers: Short pre-existing polynucleotide chain to which new deoxyribonucleotides can 
be added by DNA polymerase.  
 
Pre-implanted embryo: Embryos prior to their implantation into pseudo-pregnant 
females 
 
Pseudo-pregnant: False pregnancy. The term sometimes refers also to the premenstrual 
stage of the endometrium because it resembles the endometrium just before implantation 
of the blastocyst. In this thesis, pseudo-pregnant females were referred to the mice that 
embryos at the blastocyst stage could be implanted into in order to continue the embryo 
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INTRODUCTION & LITERATURE REVIEW 
 
Following numerous reports on mitochondrial defects in degenerative diseases, aging and 
cancer, there has been a great interest in the field of mitochondrial medicine to gain a 
better knowledge of the complexities of mitochondrial genetics and the pathophysiology 
of these mitochondrial diseases 1, 2. 
 
Mammalian mitochondria have their own genetic system that has a high sensitivity to 
mutations caused by metabolic and environmental sources 1, 2. Several clinical studies 
have provided us with some understanding of the mitochondrial genetics in these diseases 
that are caused by mutations arising in the mitochondrial DNA (mtDNA) and the nuclear 
DNA. The pathophysiology of these diseases on the other hand, remains to be answered 
as many patients display a clutter of clinical features or a clinically heterogeneous group 
of disorders that arise due to dysfunctions of the mitochondrial respiration system 1. 
Some of the clinical features include diabetes mellitus, myocardiopathy, retinitis 
pigmentosa, myoclonic epilepsy and ragged-red fiber. They also display age-associated 
changes in the functional integrity of mitochondria as seen in Parkinson, Alzheimer's and 
Huntington's diseases1. 
Mutations in the mtDNA are now known to affect tissues with high cellular energy 
requirements, such as the central nervous system, cardiac and skeletal muscle and various 





As in the case of diseases caused by nuclear encoded genes, it is important that we have 
physiologically relevant models to study the mitochondrial dynamics and mtDNA based 
diseases. Mouse models could therefore help us understand the mitochondrial dynamics, 
and diseases associated with mitochondrial DNA point mutations, deletions and 
duplications 5. Several such mouse models are currently being studied to look at the 
importance and interrelationship of the various mitochondrial functions such as the 
oxidative phosphorylation in cellular energy production, its role in apoptosis and the 
generation of reactive oxygen species 1, 2.  
 
Since several pathological conditions associated with mutations in the genes encoding for 
the proteins that function in the mitochondrial oxidative phosphorylation system have 
been reported 10,12, it has been suggested that the ability to manipulate the mitochondrial 
DNA in vitro  to alter these mutations prior to introducing the repaired mitochondrial 
genome into somatic or germ cells, could provide us with a possible long term prospect 
of gene therapy for some of these mitochondrial based diseases 4,5. Moreover, the 
creation of heteroplasmic or heterogeneous mice may provide a greater understanding of 
mitochondrial dynamics in these mitochondrial diseases. Mitochondrial isolation and 
transfer techniques would therefore be of great importance in the production of 
appropriate mouse models in generating mitochondrial disease based therapies4, 5.  
In this project, I aim at providing initial studies where the fate of mitochondria from one 
mouse strain injected into embryos of a different strain can successfully be analyzed with 
the help of novel techniques and analytical methods. This will be done by looking at the 





developmental stages. I attempt at answering the question of whether or not the foreign 
mitochondria is sequentially eliminated through embryo development and in addition, 
how we can improve on existing methodology in the production of heterogamous mice. 
This is of great importance in future studies to help increase our knowledge of the 
abnormalities in mtDNA distribution and its effects on pre- and post-natal development.  
 
 History and evolution of mitochondria 
Mitochondrion was previously termed as various names such as blepharoblast, 
chondriomites, fila, Korner and plasmasomes, to name a few. This was followed in the 
1850’s by naming the cell structure chondros (Greek), grain (English). In the late 1800’s, 
it was noted that the ‘grains’ were similar to ‘threads’, known as mitos in Greek 9. 
In the 1890’s, it was proposed that these granules were autonomous living units, forming 
bacteria-like colonies in the cytoplasm of the host cell. The idea was much later given  
second thought following the discovery that the mitochondria possessed its own DNA 
(mtDNA) which gave rise to the ‘Endosymbiotic Theory’ by F.J.R. Taylor, in 1974. The 
theory stated that ‘The Eukaryotic cell is a multiple of the prokaryote cell’, but was later 
dismissed in 1925 9, 10. 
In 1912 and 1913, B.F. Kingsbury and O. Warburg found that these granular structures 
were associated with respiration. This led to the characterization of mitochondria as the 
‘powerhouse of the cell’10. 
Between the period of 1920 and 1930’s, the discoveries of cytochromes, heme-





the  formulation of the citric acid cycle by Krebs, and the discovery of Adenosine 
triphosphate (ATP) were reported 10. 
         
Mitochondria 
Mitochondria are now known to be small organelles (0.5-1µm) located in the cytoplasm 
of all eukaryotic cells. They generate about 90% of the total ATP which is the main 
energy supply in the cells. The number of mitochondria in the cells are dependant on the 
energy requirements of the respective organs, with one cell containing about 10-20 000 in 
somatic cells and 100 000 in oocytes. Metabolically very active organs, such as the liver, 
the brain and skeletal muscles possess the largest number of mitochondria and are the 
organs primarily affected by mitochondrial pathologies 2, 11. 
Mitochondria contain their own unique genome, the mitochondrial DNA (mtDNA) 12. 
Each mitochondrion in turn has 2-10 copies of mtDNA, which codes for some of the 
proteins involved in ATP synthesis, mitochondrial ribosomal RNA (rRNA) and transfer 
RNA (tRNA). They are however dependent on proteins encoded by the nuclear genome, 













Mitochondria are composed of two highly specialized structures, namely the internal and 
external membranes, and the matrix. 
The external membrane is made up of channels that facilitate the transport of molecules 
(up to 10 KDa in molecular mass) across the membrane. Present in the membrane, are 
enzymes that convert lipids into substrates for the metabolic cycles located in the 
mitochondrial matrix1, 2. 
The internal membrane is made up of folded cristae to increase the membrane surface. It 
is impermeable to ions, for the proper maintenance of the organelle and electrochemical 
gradient. This is important for the functioning of ATPase/ATP synthase in the production 
of ATP by oxidative phosphorylation (OXPHOS). Two other proteins are integral 
components of the internal membrane; specific channels that regulate substrate transfer 
across the membrane and complexes I, II, III and IV 1, 2. 
Located in the matrix, are enzymes for the citric acid cycle and fatty acid oxidation. It 
also contains mtDNA, mitochondrial polysomes, tRNA and various enzymes required for 
the autonomous replication, transcription and translation of the mtDNA1, 2. 
 
Mitochondrial genetics 
The human mitochondrial DNA is a circular, double stranded D-loop with a size of 16-17 
Kb. The mtDNA is the smallest genome in the animal kingdom, retaining 13 polypeptide 
genes all of which encode essential components of the OXPHOS. It also encodes the 12s 
and 16s rRNA genes and the 22 tRNA genes required for the mitochondrial protein 





DNA and RNA polymerases, the ribosomal proteins and the mitochondrial transcription 
factor A (Tfam) are all encoded by nuclear genes13, 14, 15. 
Several features distinguish the mitochondrial genome from the nuclear genome. MtDNA 
is maternally inherited, being transmitted with the oocyte cytoplasm. The low amounts of 
paternal mitochondria contained in spermatozoids, have now been shown to be 
eliminated in the embryo. The paternal mtDNA thus has an insufficient effect on the 
mitochondrial content in the offspring 16. The mitochondrial genome also differs in that it 
does not replicate in synchrony with cell division.  
The lack of histones and perhaps the absence of an efficient and accurate DNA repair 
system are thought to result in the high frequency of mutations observed in the 
mitochondrial genome (10-100 times more than in the nuclear genome) 1, 2.  
The other difference in the mtDNA and the nuclear DNA would be that inherited genetic 
disorders caused by mutations in the nuclear genome are present in every cell of the 
individual where as patients with mitochondrial disease rarely have only mutant mtDNA 
(homoplasmy). The wild-type and mutant mtDNA coexist in the cells (heteroplasmy) and 
the amount of both types varies between tissues and cells throughout life, owing to the 
random distribution of mitochondria into the daughter cells during cell division. As the 
mutant mtDNA increases, the cellular energy capacity decreases until it falls below the 
bioenergetics’ threshold. Once this minimum energy output which is necessary for a cell 








Mouse models of mitochondrial disease 
Several mouse models are currently being studied to understand the importance and 
interrelationship of the various mitochondrial functions, such as the oxidative 
phosphorylation in cellular energy production, its role in apoptosis and the generation of 
reactive oxygen species 1, 2. Four well known models that have been reported are 
discussed here. 
 
• Ant - deficient mice 
Targeted inactivation of the nuclear-encoded Ant-1 gene has provided a model for 
chronic ATP deficiency. Surprisingly, ANT-1-deficient (Ant 1-/-) mice are viable, 




Mitochondrial diseases have been known to be related to the low or decreased production 
of ATP and the toxicity resulting from increased production of reactive oxygen stress 
(ROS). Subsequently, ROS have been reported to be implicated in a variety of 
degenerative diseases including Parkinson, Alzheimer disease and aging 20. 
Mitochondria generate ATP by the process of oxidative phosphorylation during which, 
the oxygen consumed is reduced to form superoxide anions which are then further 
reduced by the superoxide dismutase (SOD) into H2O2. The H2O2 is later converted into 
water or gives rise to ROS. The study of the increased ROS production has been reported 





Two mouse lines lacking MnSOD (sod2) were constructed, namely the sod2tm 1 cje and 
sodtm 1 Leb (16). The sod2tm 1 cje mutation on the CD1 background resulted in death from 
dilated cardiomyopathy. The sodtm 1 Leb mutation in the C57BL/6 caused the death 
associated with neuronal degeneration in the basal ganglia and brain stem 20, 21. 
 
• Disruption of the mouse gene for mitochondrial transcription factor (Tfam) 
The production of Tfam deficient mice was reported in 1998 by a team of scientists that 
inactivated the nuclear gene that encodes mitochondrial transcription factor Tfam. This 
may thus provide a model for mtDNA deletions. This was accomplished by targeting the 
gene of loxP-sites and eliminating the terminal two exons by crossing the +/Tfam loxP 
mice with mice bearing the cre recombinase gene under control of the β-actin gene 
promoter 22. The resultant heterozygous knockout mice, showed a reduced mtDNA copy 
number and respiratory chain deficiency in the heart. In this way, they successfully 
showed Tfam to be a mammalian protein, which regulates the mtDNA copy number in 
vivo and essential for mitochondrial biogenesis and embryo development 22. The mutant 
mice produced in the above experiment showed a level of Tfam in the hearts and later 
died of dilated cardiomyopathy. Some of the cardiomyocytes were COX- and SDH+, 
which resembles the mosaic oxidative phosphorylation deficiencies that were seen in 
human mitochondrial myopathy patients, reported earlier 23.  
 
• The introduction of foreign/ mutated mtDNA into the female germline 
As much effort is being made to create various models in order to study mitochondrial 





accurately show the genetics of mtDNA diseases2. As explained below, attempts at 
introducing foreign or mutated mtDNA into the female mouse germline have been 
reported.  
 
-CAPR mtDNA mutations 
A possible model for the study of human mitochondrial protein synthesis diseases has 
been reported 24. In this study, a CAPR mtDNA mutation was introduced into the female 
germline. This was then used as a model since the mutation is known to alter the 
mitochondrial ribosome function, thus resulting in a decrease in complex I and IV 
activities 24, 25, 26.  
CAPR mtDNA from the 501- 1 cells mice were used in order to track the mtDNA using 
the 501-1 CAPR point mutation in the 16s rRNA gene. The CAPR mtDNA mutation was 
introduced into the female embryonic stem cells by cybrid transfer. These were then 
microinjected at the blastocyst stage in order to introduce them into the female germline 
24, 25, 26.  
 
-foreign mtDNA introduction into the female germline 
With the goal of creating various models to study mitochondrial diseases, it would be 
necessary to be able to alter the mtDNA and secondly, to introduce the altered mtDNA 
into the female germline. Therefore, an alternate approach taken by some scientists has 
been to attempt the successful introduction of foreign mtDNA into the female germline.  
In one such study, heteroplasmic mice from two inbred strains (NZB/BinJ and BALB/c) 





study the mitochondrial pattern of segregation by random genetic drift occurring in early 
embryogenesis 27, 28. By Electro-fusing the embryos from the BALB and NZB females, 
they produced embryos containing the two mtDNA genotypes and re-implanted them into 
B6C3F1 females 27. The F1 offspring carried mtDNA of both genotypes following 
analysis of mtDNA from the tail biopsies. Later in 1997, analysis of both mtDNA 
genotypes showed that the heteroplasmic mice displayed a genetic drift in some tissues 
and in others a strong tissue-specific and age-related directional selection for the different 
mtDNA genotypes in the same animal 28. The NZB genotype was selected in liver/kidney 
and the BALB genotype was selected in the blood/spleen27, 28. 
 
In the second study, mitochondria from the somatic cells of M.Spretus mice were 
microinjected into ova of the M.Mus.Domesticus. These are two distinctly related species 
of mice 4, 5. Using species specific nested PCR primers that were designed 
complementary to the sequence differences in the D-Loop, they reported the successful 
transfer and detection of the mitochondria. M.Spretus mitochondria isolated from the 
liver was detectable in the blastocyst embryos following in vitro culture of the embryos 4, 
5. They later produced heteroplasmic mice by successfully reimplanting the 
micromanipulated embryos into pseudo-pregnant females. The F1 mice showed 
detectable levels of M.Spretus mitochondria5. However, in the reported study, the 
isolation of the mitochondria from the heterogeneous embryos created in order to detect 







In this thesis we provide methodology for the introduction of foreign mtDNA into the 
female germline which can later be used in the production of appropriate mouse models 
in studying mitochondrial diseases.  
 
Firstly, methodologies studying the morphological changes in the preimplanted embryos 
are presented. This includes criterion for selecting viable embryos showing good 
development and a high percentage success rate of development to the blastocyst stage in 
vitro. Embryos selected using this criterion have been reported in previous studies to have 
a high potential for implantation into the pseudo-pregnant female29, 30. This would be 
crucial in selecting embryos for all further experiments including the micromanipulation 
and implantation into pseudo-pregnant females in creating mouse models. 
 
In addition, methodologies for studying the mitochondrial distribution and relocation 
patterns of active and non-active mitochondria in the various stages of embryonic 
development in vitro are also reported. This would provide us with a better knowledge of 
the mitochondrial distribution and relocation in healthy embryos and could also be 
replicated when studying the e fate or effects of the injected mitochondria into embryos. 
In addition,, the effects of the mitochondrial mutations that are ‘altered’ prior to their 
injection into embryo cells in vitro in future studies could be understood using this 
methodology. We would thus begin to determine the effects of these ‘altered’ 
mitochondria at the embryonic level of development in possible further studies. Studying 
the mitochondrial distribution and relocation patterns is of importance, as it has been 





embryos 30. From previous reports, the distribution is believed to be almost uniform, but 
when energy requirements are unevenly distributed, mitochondria tends to aggregate at 
sites of the energy demand 30, 63, and 64. It is also known that mitochondrial relocation and 
distribution vary with changes in cell function, such as metabolic changes, cell 
proliferation and differentiation 30, 65, 66, 67, 68, 69, 70, 71 and 72.  
Other work carried out where studies examining the contribution of mitochondrial 
oxidative phosphorylation to ATP production during the preimplantation stages have 
shown that ATP generation during pre-compaction stages is largely dependant upon 
oxidative phosphorylation, with a shift to glycolysis occurring during activation and 
blastocyst stages 5, 6. 
Similar work has focused on the morphological observation and redistribution of 
mitochondria in oocyte and early embryos in various species, in order to clarify the 
importance of mitochondria in early development 1, 3, 4, 5, 6. It has been reported that when 
development is compromised or disrupted, the distribution of mitochondria is often 
altered in comparison to normal embryo development 1, 6. Since it is known that 
embryogenic mitochondria only resume transcription and gain replicative ability 
following the blastocyst stage, each blastomere in the embryos is therefore dependent on 
the energy produced from the oocytes-inherited mitochondria 9, 10, 11.  
Although morphological criteria such as uniformity of blastomeres and rate of cell 
division (EDR) are primary determinants of embryo selection, developmental arrest of 
intact embryos in vitro and implantation failure do occur in these ‘normal’ embryos. By 
studying the mitochondrial distribution it would thus gives us added information and 





In the successful transfer of mitochondria into embryos, it is crucial to have as high a 
purity suspension with a higher number of intact mitochondria in order to increase the 
chances of intact and active mitochondria being introduced into the embryos in the small 
volumes that can be injected. Here, we attempt to improve on the isolation techniques of 
the mitochondrial suspensions to be injected into the embryos. Additionally, we provide 
an alternative simple methodology for studying the integrity of the isolated mitochondria 
prior their injection into embryos to ensure the introduction of highly active and intact 
mitochondria with as little contamination as possible.  
 
In attempting to produce a mouse model where foreign mitochondria is introduced into 
the somatic cells as described, it would ideally be beneficial to have two mice types that 
were distantly related, in order to have two mtDNA’s that illustrate a high diversity, thus 
imitating the introduction of altered mitochondrial mutations in vitro prior to being 
injected into the female germline.  
However, in this project the choice of mice was of great limitation and a major set back 
due to the occurrence of the Monkey Pox Virus in the USA. Due to these unforeseeable 
circumstances and a resulting ban on mice imports by the AVA authorities in Singapore, 
I was unable to use mice from different mice strains as initially intended. However, i 
overcame this by attempting to create heterogeneous embryos using two related sub-
strains of the Mus Musculus Domesticus species, namely the C57 and BALB mice that 
were available to us during the project. The detection of the BALB mitochondria 
(‘foreign’ mitochondria), was designed using the work of Bayona-Bafaluy M.P et al 8, 27, 





provide methodology, which would then serve as good initial steps for the production of 
appropriate mouse models in the study of mitochondrial diseases in future studies when 
the appropriate mice strains would be available.  
Using the sequence differences provided, I attempt to design the nested PCR primers for 
the COIII polymorphic site to distinguish between the two mice sub-strains used 27, 28, 39, 8, 
40. The COIII polymorphism is situated at the 9348bp site of the mtDNA sequence. The 
COIII polymorphism has been shown to be present exclusively in the C57BL/6J mtDNA 
but not in the BALB/cJ thus being able to differentiate between the two sub strains 
mtDNA’s and confirm the successful transfer of the ‘foreign’ mitochondria.27, 28.  
 
In previous experiments reported by Pinkert et al, to confirm the successful transfer of 
mitochondria into the embryos, isolation of mitochondria from individual embryos 
followed by their mtDNA isolation was performed 4,5. However this protocol was 
reported by the author to be tedious and difficulties were faced in attempting to isolate 
the mitochondrial DNA from single embryos. Therefore, in my experiments presented 
here, I have used alternative simple methodology to this, so as to avoid these 
complications and improve the efficiency of the methodology51.  
 
Furthermore I provide methodology to study the fate of the injected mitochondria and the 
native mitochondria in the embryos generated, and additionally, attempt to determine the 
concentration ratios between the native and foreign mitochondria in the embryos. I did so 
by studying the mtDNA concentrations for both the injected as well as the native 





and Balb mtDNA isolated from their respective liver samples.  This would also help us 
understand whether or not the injected mitochondria or the native mitochondria were 
decreasing in concentrations or appear to be diluted out during sequential cleavage of the 
embryos as an embryonic defense mechanism to the foreign mitochondria. This would be 
interesting to study as it has been reported that the few sperm mitochondria that enter the 
oocyte at fertilization appear to be degraded or diluted out during embryonic 
development and cannot be detected at the blastocyst stages 45,46.  
 
This study would also help us answer several questions on whether the methodology 
presented here was successful by confirming that the injected mitochondria remains 
present in the embryos up to the blastocyst stages in vitro, following their 
micromanipulation or does the amount of mitochondrial suspension injected into the 
embryos need to be of a certain volume to remain present in the embryos at the blastocyst 
stage prior to being implanted into the pseudo-pregnant female mice. Furthermore, this 
methodology could prove important in future studies, to observe the concentration ratios 
between the native and foreign mtDNA as there could be a threshold at which the 
therapeutic effects of the mtDNA that has been manipulated in vitro to correct certain 
mutations may possibly begin to manifest at the embryonic level. This may prove 
valuable in further studies as we progress in our knowledge in mitochondrial medicine. 
 
In this thesis presented here, several experiments were designed to answer the various 
questions and objectives I set out to answer. Firstly, embryo morphology was studied to 





point for studying the effects and development of the embryos following their 
micromanipulation.  
Secondly, the location and relocation of active and non-active mitochondria in embryo 
development was studied. This was also done to provide good replicable methodology for 
further studies where the effects of foreign and native mitochondria can be studied on 
each other in the future. By doing so, we can gain a better insight on the effects of altered 
mitochondria on the existing ones in the micromanipulated embryos and study the 
therapeutic effects of altered mitochondria introduced onto embryo cells.  
Using the sequence differences to design primers specific to the individual mtDNA’s of 
two mice strains, I set out to design a third experiment to study the fate of injected 
“foreign” mitochondria. In this experiment, several questions are intended to be 
addressed, firstly, the successful introduction of the foreign Balb mitochondria into the 
embryos of C57 mice. Secondly, it would answer the question of whether or not the Balb 
mitochondria is sequentially eliminated from the embryo over the development of the 
embryos as a defense mechanism of the embryo and in addition, whether or not the 
foreign mitochondria has any effect on the native mitochondria concentrations over 
development to the blastocyst stages.  
This thesis therefore attempts to provide detailed and reproducible methodology which 
can serve as good initial steps for the production of appropriate mouse models in studying 
mitochondrial diseases in future studies. These mouse models could in turn help us 
further our knowledge in the field of mitochondrial medicine and expand our awareness 































2.1 MORPHOLOGY OF MOUSE EMBRYO DEVELOPMENT In Vitro 
 
2.1.1 Choice of Mice 
 
 C57/CBA F1 hybrid female mice, Swiss albino male mice and BABL/c inbred female 
mice were obtained from the Animal Laboratory Care Centre (LAC), Sembawang, 
Singapore, supplied for the National University of Singapore. The mice were 
acclimatized to the room conditions. Window-less rooms provided with time-controlled 
lighting of 12 hour light and dark conditions were used to house the mice. The 
temperature and humidity were maintained at 22°C and 55±10% respectively. 
 
 
2.1.2 Mice properties  
 
Female BALB/c mice are inbred strains from the Mus Musculus Domesticus strain of 
mice as shown in figure 1 below. Inbred strains obtained from the animal holding unit are 
produced by 20 or more consecutive generations of brother x sister mating with all 
individuals being traced from a common ancestor in the 20th or subsequent generation. 
Inbred mice were chosen for this study as they are a more uniformed strain, better defined 
and genetically more stable than outbred/random-bred stock. Inbred mice are also known 






Female C57/CBA F1 hybrid mice are a first generation cross between two different 
inbred strains. C57/CBA F1 mice belong to the Mus Musculus Domesticus strain and are 
inbred mice (figure 1). The standard nomenclature requires the strain of the female 
breeder to be given first followed by the male breeder. i.e.; C57 x CBA F1 hybrid has a 
C57 strain female breeder and a CBA strain male breeder. C57 and CBA are both from the 
Mus Musculus Domesticus strain of mice. The 5-6 week old C57/CBA F1 females are 
known to be good breeders and since mitochondrial DNA is maternally inherited, these 
mice were chosen as females providing the embryos for the study of C57 mtDNA.  
 
Swiss Albino male mice (Mus Musculus Domesticus) (Fig 1) that were outbred were used 
at the age of 7-8 weeks to mate with the Superovulated C57/CBA F1 females for all 
studies carried out.  
 
A taxonomy chart of the Murinae (Mice) strains is described here in figure 1. The major 
strains such as the Mus Musculus Domesticus used in our studies along with Mus. 











































 Mus Cookii   Mus Mus Musculus praetextus   (Mice) 
Mus Musculus wagneri  
Mus Pahari  
 
 
Mus Musculus homourus  
 
 
C57/CBAMus Spretus  




Mus Musculus Castaneus  
 
NZB 
Mus Musculus  




Mus Musculus gentilulus  
 
 
 Mus Musculus molossinus  
 
 
 Mus Musculus musculus  
 
Figure 1:  Taxonomy chart of Murinae (Mice), showing Mus Musculus Domesticus, 




2.1.3 Collection and treatment of fertilized embryos in vitro 
2.1.3.1 Superovulation of Mice 
Mice were Super-ovulated to produce larger batches of synchronous embryos than would 
not possible with natural mating. 
C57/CBA F1 hybrid female mice aged 5-6 weeks old were stimulated by intra-peritoneal 
(i.p.) injection of 10-IU pregnant mare’s serum (PMSG) (Folligon, Intervet International 
B.V., Boxmeer, Holland), followed 46-48 hrs later with 10-IU of human chorionic 
gonadotropin (hCG) (Coluron, Intervet International B.V., Boxmeer, Holland). The 
hybrid females were left over night to mate with Swiss Albino male mice aged 7-8 weeks 
old. The following morning, the females were checked for vaginal plug. The mice with a 
















2.1.3.2 Recovery of Mouse Embryos 
Sixteen to eighteen hours post hCG administration, the female mice that were considered 
pregnant were sacrificed by cervical dislocation. The mice were laid on its back and the 
abdomen swabbed with 70% ethanol. An incision was made in the midline and the skin 
pulled towards the head until the abdomen wall was completely exposed. The peritoneal 
cavity was opened and the two uterine horns located. The upper end of the uterine horn 
was then grasped and pulled gently, thus putting the uterine horn on traction. A cut was 
carefully made between the oviduct and the uterine body and also between ovary and 
oviduct using a fine scissor. The oviduct and attached segment of uterus was then 
carefully placed in a multi-well dish containing 1ml of CZBH medium. The oviducts 
were then placed into a 35mm Petri dish (Becton Dickinson, New Jersey, USA) 
containing CZBH medium for the recovery of the oocytes. 
 
Recovery of embryos were carried out under a 20X magnification on a stereo microscope 
(Nikon, SMZ-10, Tokyo, Japan) equipped with a stage warmer set at 37°C in a well 
ventilated hood. The oocytes were then teased from the oviduct. The clutch of ovulated 
oocytes surrounded by cumulus cells (the oocyte-cumulus-corona complex, OCC) was 
located in the ampulla or swollen upper part of the oviduct. The oocytes were then 
released from the ampulla using two 25 gauge needles, one to grasp the oviduct firmly to 







To remove the cumulus cells, the clutch of embryos were placed in CZB medium 
droplets containing hyaluronidase. The embryos were exposed to 0.1% hyaluronidase 
(Type II, sheep testes, Sigma Chemical Company, St.Louis, Mo, USA) for five minutes. 
They were then carefully washed through four droplets of CZB medium and cultured in 
CZB droplets under paraffin oil for incubation under 37°C, 5% CO2 in air.  
 Embryos were transferred using carefully sterilized pipettes. The pipettes under went a 
thorough sterilization process where they were washed 10 times with milli-Q processed 
water, dried and sterilized at 1500 C for 4 hours. The pipettes where packed in 
autoclavable pouches and sealed for sterile autoclaving. These pipettes were then used for 

















2.1.3.3 Assessment of Fertilization 
Oocytes with two pronuclear (Male and Female) and second polar bodies present were 
considered to be fertilized. The fertilized oocytes (Zygotes) were then separated from the 
rest and allowed to grow to the blastocyst stage.  
 
2.1.3.4 Assessment of Embryo development and quality 
Normal embryo development has been extensively studied and well established criteria 
are available for the assessment of mouse embryo development 29. In this study, the 
scoring system used for embryo viability and development, was the Embryo 
Development Rating (EDR) system. This was a percentage of the number of viable 
embryos recorded at various times that had successfully grown to the expected stage of 
development. Only the embryos that had successfully grown to their expected stage and 
showed morphology resembling that of viable embryos were selected 29. 
All embryo viability studies were conducted under a 20X magnification on a stereo 
microscope (Nikon, SMZ-10, Tokyo, Japan) equipped with a stage warmer set at 37°C in 


















2.2 MITOCHONDRIAL DISTRIBUTION PATTERN IN 
PREIMPLANTED EMBRYOS 
 
2.2.1 Mitotracker green FM and rhodamine 123 dyes 
The distribution pattern in early mouse embryo development was studied using 
Mitotracker green FM dye (Molecular Probes, inc. Eugene, USA) and rhodamine 123 dye 
(Molecular Probes, inc. Eugene, USA) and analyzed using an Olympus Flouview 
scanning laser confocal microscopy (SLCM).  
 
The Mitotracker Green FM used in this study is a mitochondrion selective dye that 
accumulates in mitochondria regardless of mitochondrial membrane potential, thus 
labeling all active and non-active mitochondria. Embryos were incubated with nanomolar 
concentrations of the dye which exhibited a bright green fluorescence upon analysis with 
a confocal scanning microscopy. 
Mitotracker Green FM has the added advantage over other available dyes in that it is 
essentially non-fluorescent in aqueous solutions and becomes fluorescent only when 
accumulated in the lipid environment of mitochondria. Hence, background fluorescence 
is negligible, enabling a clear analysis of mitochondrial distribution in live embryos 
following addition of the stain. Due to its emission maxima being more blue-shifted, 
approximately 10nm relative to the emission maxima of rhodamine 123, mitotracker 
green FM produces a fluorescent staining pattern that should be better resolved from that 




Rhodamine 123 is a cell-permeant fluorescent dye that is readily sequestered by only the 
active mitochondria. Viewed through a tetramethylrhodamine long pass optical filter, the 
mitochondria appear red. Rhodamine 123 is a lipophilic cation probe, whose 
incorporation depends mainly on the potential of membrane. 
 
 
Here we carried out a study the mitochondrial distribution in all preimplanted stages 
using the mitotracker green FM dye that stains all active and non-active mitochondria so 
as to get a better knowledge of the mitochondrial distribution irrespective of its activity. 
Additionally, we performed staining using a rhodamine 123 dye that stains only the 
active mitochondria in order to get a rough visual quantity and distribution pattern 
comparison of the active and non active mitochondria in the embryos.  
These two dyes were chosen as the dyes of choice as there are no commercially available 
dyes to our knowledge that stain only the non-active mitochondria. Additionally, green 
FM can be used in double staining experiments and used on live cells without the need to 
fix the cells prior to or following the staining. 
Commercially available mitochondrial dyes have a disadvantage in that they cause 
toxicity in embryos if left to culture for several days. Therefore, liver embryos were 
stained at the various stages. These embryos were not further cultured. 
As we did not have the available technology to make accurate quantity comparisons, a 
visual comparison of the quantity and distribution pattern of the mitochondria was used. 
A double staining was performed only in the early embryo development at the one and 




2.2.2 Embryo Staining with Mitotracker green FM and Rhodamine 123 
The Lyophilized dye was prepared by dissolving in anhydrous dimethylsulfoxide 
(DMSO) and protected from light. A working concentration of 8µg/ml for the staining 
using the Green Fm dye and a 10µg/ml of the rhodamine 123 dye were used. For the 
MitoTracker Green FM, a slightly lower concentration (20– 200 nM) was used as a 
higher concentration is reported to stain other cellular structures. 
Embryos consisting of 25 embryos per embryo stage were stained for an optimized time 
of fifteen minutes in a light protected container. The staining time was optimized to a 
fixed 15 minutes that was reached by initial studies to inspect  sufficient staining under a 
fluorescent microscope for individual staining of Green FM or Rhodamine 123 and also 
for the double staining using both dyes. 
 The stained embryos were then washed through three droplets of CZB medium 
containing 0.55M glucose before transferring them to a slide dish with a 50µl droplet of 
CZB. The droplet was covered with embryo tested mineral oil for immediate analysis 
using confocal scanning microscopy. 
 
2.2.3 Laser Confocal Microscopic analysis 
Scanning laser confocal microscopy (SLCM) images were obtained using an Olympus 
Flouview confocal microscope equipped with an argon laser excitation at 488nm. The 
Signal was collected using an emission filter of 510-525 BP for the Green Fm study, 
while an excitation wavelength of 507nm and an emission wavelength of 529nm for the 






2.2.4 Embryo selection for mitochondrial staining  
To ensure the study of mitochondrial distribution was that of only viable embryos with 
‘normal’ or healthy development, all embryos selected for this study were selected as 
viable using the Embryo Development Rating (EDR) system discussed earlier. 
Control embryos consisted of six embryos per developmental stage studied. Untreated 






















2.3 MICROINJECTION OF MITOCHONDRIA INTO EMBRYOS 
-MITOCHONDRIAL PREPERATION: 
 
2.3.1 Isolation of enriched and functional mitochondrial fractions for microinjection 
Since the mitochondrial suspension that is to be injected into the embryos would be of a 
minute quantity, it would be critical to have an enriched suspension that contained a high 
number of viable and active mitochondria, in order to maximize the number of viable 
mitochondria being injected into the embryos.  
 
To ensure this, a mitochondrial isolation kit (Sigma-Aldrich, St. Louis, Mo, USA) was 
used that enables the fast and efficient isolation of an enriched mitochondrial fraction 
from the liver tissues. The Mitochondrial isolation Kit also allows for the testing of the 
electrochemical proton gradient (∆Ψ) of the inner mitochondrial membrane. This was 
done by measuring the uptake of a JC-1 dye using a spectro-flourometer 41.  
 
Following the isolation and testing of the mitochondria, the mitochondrial suspension 
was tested for mitochondrial protein concentration using a simple biuret test. The final 
working protein concentration of the mitochondrial suspension used for microinjection 
into one cell embryos was 10-15 mg/ml. Fresh mitochondrial suspensions were isolated 
immediately prior to their micromanipulation into the embryos. All suspensions were 
maintained at 4°C at all times of the isolation procedure to maintain the integrity of the 





2.3.2 Preparation of mitochondria from liver tissue 
 
A fresh tissue sample obtained immediately after the sacrifice of the mice was placed into 
an extraction buffer containing 10mM HEPES pH 7.5, containing 200mM mannitol, 
70mM sucrose and 1 mM EGTA and maintained on ice. All solutions used were part of 
the mitochondrial isolation kit (Sigma-Aldrich, St. Louis, Mo, USA) and were sterile and 
autoclaved (see appendix for buffer compositions). During the procedures for the 
isolation of mitochondria from liver sample, the suspensions were kept on ice and 
maintained at 4°C at all times to maintain the integrity of the mitochondria.  
The samples were washed twice in an extraction buffer. 50-100 mg of the tissue was 
weighed and cut into small portions using a fine scissor and homogenized in a 2ml hand-
held homogenizer with a 10 times volume of the extraction buffer containing 2mg/ml 
albumin. 
After homogenizing the tissue with 60 strokes to ensure complete homogenization, the 
homogenate was placed in 1ml eppendorf tube and centrifuged at 600 x g for 5 minutes. 
The supernatant was carefully transferred into a clean eppendorf tube and further 
centrifuged at 11,000 x g for 10 minutes. The supernatant was discarded and the pellet re-
suspended in the extraction Buffer containing 2mg/ml albumin.  
After repeating the centrifugation at 600 x g for 5 minutes and centrifugation at 11,000 x 
g for 10 minutes, the pellet was re-suspended in 40µl/100mg tissue of the storage buffer 
of 10M HEPES pH 7.4 containing 250 mM sucrose, 1mM ATP, 0.08 mM ADP, 5mM 




The Mitochondrial concentrations were assayed using a standard biuret protein test. 
Concentrations of 10-15mg/ml were prepared for immediate microinjection into the one 
cell embryos. The analysis of mitochondrial potential (inner membrane integrity) was 
carried out to confirm intact and viable mitochondria by measuring the JC-1 dye uptake 






















2.3.3 Mitochondrial Integrity Study using JC-1 Dye 
The integrity of the inner membrane of the mitochondria was analyzed by measuring the 
uptake of the fluorescent carbocyanine dye (JC-1). The integrity of the inner 
mitochondrial membrane was measured by observing the potential gradient (∆Ψ) over the 
membrane by measuring the uptake of the cationic carbocyanine dye JC-1 (5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenz-imidazolcarbocyanine iodide) (Sigma-Aldrich, St. 
Louis, Mo, USA)  into the matrix using a spectro-flourometer. 
The flourophore JC-1 has the property that when excited at 490 nm, the emission 
spectrum will be dependent on the concentration of the molecule. In dilute solutions of 
≤300 nM it will give a green fluorescence at 527 nm, but when the concentration is 
greater than 1 mM, a very strong red-orange fluorescence will occur at 590 nm.  
Active mitochondria display a high change in membrane potential (∆Ψm), while inactive 
or dead mitochondria display a low ∆Ψm 41. When the ∆Ψm is high, the dye crosses the 
membrane and forms J-aggregates which appear red under UV light. A low ∆Ψm results 
in the dye remaining in the monomeric form and fluoresces green. Thus, we would ensure 
the injected suspension to be of intact mitochondria with high activity. 
 
The JC-1 dye was dissolved in 25µl of dry DMSO to give a 1 mg/ml solution. The 
solution was stored at 20 °C for further studies.  
The 1X JC-1 Assay Buffer made of 20 mM MOPS (pH 7.5) containing 110 mM KCl, 10 
mM ATP, 10 mM MgCl2, 10 mM sodium succinate and 1 mM EGTA was diluted in 




The mitochondrial suspension was diluted in the storage buffer to a 1mg concentration. 
This was then diluted to a 5µg, 20µg and 40µg protein concentrations to perform the JC-1 
assay at increasing mitochondrial protein concentrations. These increasing protein 
concentrations along with a blank sample containing no protein was prepared with the 
appropriate buffers as described below for the JC-1 assay to a total of 2mls, each made up 
with the storage buffer. A table was used to record all experimental quantities for further 
calculations as shown in table 1 below. 
 
Table 1: Sample Preparations for JC-1 Assay 
Sample Assay 
Buffer 
















1.9ml 100µl minus 5ug    5µg 2µl 
1.9ml 100µl minus 20µg   20µg 2µl 
 
Mitochondrial 
Sample 1.9ml 100µl minus 40µg   40µg 2µl 
 
The reaction was started by the addition of 2µl of the JC-1 Stain and mixed. The reaction 
was left for a recommended seven minutes to allow for complete uptake of the dye. The 
test tubes were covered with aluminum foil so as to prevent any photo-bleaching and 
were maintained at room temperature. The fluorescence was read using a spectro-
flourometer set at an excitation wavelength of 490 nm and the slit set at 5 nm. The 




calculated per mg mitochondrial protein (FLU/mgP) using the following formula and 
plotted into a graph for a linear presentation of the JC-1 uptake versus the amount of 
mitochondrial. 
FLU/mgP = (∆FL) x dil/ V x C  
          FLU= fluorescence units 
          mgP= milligram protein 
            ∆FL = FLsample - FLblank 
            dil = dilution factor to prepare 1 mg/ml suspension  
             C = mgP/ml 


















2.3.4 Mitochondrial DNA isolation from Liver Mitochondrial suspensions 
 
Mitochondrial DNA was isolated from a partial liver mitochondrial suspension 42, 4, and 5. 
The mitochondrial DNA from liver samples was isolated to test the Nested PCR primers 
for standardization, carry out control experiments and carry out comparative experiments 
on the liver mtDNA and the heterogeneous embryos generated.  
 
Mitochondrial samples from liver tissues where prepared as described earlier. 
Mitochondrial suspension was resuspended in 200µl of Buffer A and kept on ice. To lyse 
the mitochondria and denature the nuclear DNA, 400µl of 1% alkaline SDS solution 
containing 0.2 M NaOH was added to the mitochondrial suspension. The mixture was 
thoroughly mixed and incubated for 5 minutes on ice. This was followed by adding 300 
µl of 3M potassium acetate to the mixture and the eppendorf tube gently mixed. The tube 
was maintained at -70°C for 2 minutes. After centrifuging the tube at 10 000 x g for 10 
minutes, 750 µl of the supernatant was placed in a clean tube and the mtDNA was 
precipitated using 450 µl isopropanol. The tube was incubated at -70 °C for 5 minutes 
and the precipitate collected by centrifugation at 10 000 x g for 10 minutes. The 
supernatant was carefully discarded making sure not to dislodge the pellet. If the pellet 
were to dislodge, the tube was further centrifuged. The pellet was then washed twice with 
70% ethanol and re-suspended in 100 µl of TE Buffer containing 10mM Tris-HCL and 






A Phenol: chloroform extraction was performed twice using Phenol: chloroform: isoanyl-
alcohol (25:24:1) at a pH 8.0. Equal volume of phenol: chloroform were added to the 
tube and mixed. The sample was then centrifuged at 10 000 x g for 5 minutes. 90% of the 
supernatant was removed taking care as to avoid the protein containing inter-phase. The 
supernatant was placed in a fresh tube and the phenol: chloroform extracted twice using 
chloroform. The tube was further centrifuged at 10 000x g for 5 minutes and the 
supernatant placed in a fresh tube.  
 
The mtDNA was then precipitated using isopropanol and washed with 70% ethanol as 
described above. The precipitate was dried following the wash with 70% ethanol and re-
suspended in 100 µl TE buffer.  
The purity and concentration of the mtDNA samples were measured by assessing the 













2.4 MICROINJECTION OF MITOCHONDRIA INTO EMBRYOS 
-PREPERATION FOR MICROMANIPULATION: 
 
2.4.1 Embryo selection for micromanipulation 
For this study, C57 fertilized embryos were recovered and the one cell embryo 
morphology examined for selection of high quality embryos as described earlier. 
 
2.4.2 Source of Micro tools 
Pasteur pipettes were used for fabrication of holding pipettes. Microinjection pipettes 
were prepared from borosilicate glass capillary tubes (Drummond Scientific Company, 
Broomall, PA, USA) of 300 mm length and an inner and outer diameter of 0.75 mm and 
1.0 mm respectively.  
 
2.4.2.1 Making the Holding Pipette 
The holding pipette is a suction pipette which is used to hold the oocyte in place while 
the micromanipulation procedure is being performed. Briefly, a 10cm glass capillary tube 
was pulled either using a micro-burner, or a horizontal microelectrode puller (P-87, Sutter 
Instrument, California, USA).In the first technique, the capillary is held with both hands 
and heated at the center by rotating it in the flame of a micro burner. To obtain the fine 
diameter required, the capillary was drawn out to approximately 1 cm while still in the 
flame, followed by a second very hard pull to draw out a thin region 5-10cm long. In the 
second technique, the pipette is placed on the horizontal microelectrode puller and locked 




pipette. Following either techniques, the outer diameter of the drawn out region was then 
checked under a microscope. The outer diameter of the pipette should be approximately 
80-100µm in diameter in order to get an outer diameter close to the diameter of the zona 
pellucida of the embryo. Too large a diameter will have an orifice higher than the equator 
of the zona pellucida. On the other hand, too small a diameter would result in a pipette 
that would not have a sufficient grasp onto the embryo due to its small diameter. 
Therefore, the holding pipette diameter is crucial in performing a smooth and hassle free 
micromanipulation.  
 
The pipette is broken 1-2 cm from the shoulder of the pipette, to give a perfect flush tip, 
by supporting the drawn-out region of the pipette with the tip of a finger and using 
another piece of capillary tubing held perpendicular to the drawn-out pipette to press 
down lightly on the drawn-out piece and stroke the capillary away from you. When 
sufficient force is exerted on the pipette, it breaks, leaving a perfectly flush end. The 
pipette is examined under the stereomicroscope to ensure a clean cut and a perfect flush 
tip. 
 
The pipette was clamped into the De Fonbrune micro forge (MF-1, Technical Products 
International Inc, St.Louis, Mo, USA) in the vertical position using a leitz instrument 
tube. The drawn tip of the pipette was positioned so that it was directly above the heating 
filament of the micro forge. Using an eyepiece equipped with a micrometer to observe 
the diameter, heat the filament and position it close to the tip of the pipette until it melts 




pipette was once again inspected using the micrometer for the correct inner and outer 
diameter and for a straight tip (a tip pointing towards one side would cause difficulty in 
the microinjection process). The tip should be smooth and perpendicular to the long axis 
of the pipette. 
 
The pipette was then bent at a point 2-3mm from the tip at an angle to allow the pipette to 
be positioned horizontally in the injection chamber. The filament was carefully heated to 
bend under its own weight to an angle of 35°. The holding needles were stored for future 
use in individual needle holders designed to protect them from any damage and any 
external contamination. This would prevent any clogging with dust or foreign particles 
















2.4.2.2 Making the Injecting Pipette 
Thin-walled glass capillary tubing’s were used to prepare the injection needles. A 
mechanical pipette puller was used to pull a piece of 10-15cm long with an outer 
diameter of 1mm or 1.5mm.The pipette puller was set to heat and pull the pipette to 
produce a diameter of less than 1µm, which is too small to visualize with a light 
microscope. (Pipettes with large tips are difficult to insert into the pronucleus and tend to 
lyse many of the eggs; however, if the tip is too small, it will clog very easily). 
The tip was then cut to a diameter of 3-5µm by melting it with a hot filament. Grind the 
tip at a 40 to 45°angle, on an abrasive grinding wheel. This yields a pipette tip with a 
larger opening that allows the mitochondrial suspension to flow out of the pipette with 
ease and at a controllable rate. 
Using a glass-ball on the filament, the needle tip is spiked by touching the tip of the 
pipette to the heated glass-ball for a second and retreat the needle back out quickly. This 
produces a short and sharp spike at the pipette tip for an easy injection of the Oocyte with 
minimum damage to the Oocyte in the process. The needle was bent to an angle of 30-
35° as described for the holding pipettes. 
The injecting needles were prepared the same day they were to be used, as old needles 









2.4.3 MICROINJECTION PROCEDURE 
 
2.4.3.1 Micromanipulator set-up 
The micromanipulator comprises of a tool holder that holds the needle in place, silicon 
tubing and a graduated syringe supported by a body. It was first checked for any 
unwanted bubbles trapped to prevent any bubbles from causing sudden uncontrollable 
force from occurring. During the microinjection of the mitochondrial suspension, this 
would disrupt the integrity of the embryo and cause damage by uncontrolled/excess 
injection of the mitochondrial suspension into the embryo. 
The micromanipulator was set up as shown in figure 2 and was then optimized to enable 
a smooth and slow expulsion of mitochondria. The needles were then aligned to the same 








Figure 2: Micromanipulator Setup 43. A. Micrometer / Hydraulic Drive Unit, B. 
Micromanipulator, C. Inverted light stereomicroscope, E. Injecting needle D. Needle holder / 





2.4.3.2 Injection of Mitochondria into Embryos 
The Embryos were placed in a Petri dish containing five droplets, each containing 5µl 
CZBH medium. The dish was then covered with 2mls Embryo tested mineral oil as 











CZBH medium droplets 






Figure 3: Preparation of Petri dish containing embryos and mitochondrial suspension 











The microinjection pipette was used to directly inject the mitochondria into the cytoplasm 
of the embryo. The microinjection was performed on an Axiovert 35M iverted 
microscope with an inbuilt stage warmer. The microinjection procedure is then carried 
out on the 37
o
C heated stage of the microscope with magnification of 50,100 and 200X.  
 
The microinjection pipette, which accommodated mitochondria from the droplet, was 
then slowly advanced through the zona pellucida and directly into the cytoplasm of the 
embryo at a 3 O’clock to 9 O’clock direction by moving the joystick accordingly as 
shown in figure 4. A small volume of the mitochondrial suspension was dispensed slowly 
into the embryo.  
The mitochondrial suspension was injected into the embryo causing a small increase in 
the cytoplasmic volume. This has been predicted to be a 3-5pl volume by Pinkert at al: 
97. This could be seen almost as a small vacuole being injected into the embryo Extreme 
care was taken so as not to disrupt the embryo in any way and similarly not to increase 
the cytoplasmic volume drastically which would rupture the embryo or possibly interfere 
with the embryo development. A collective pictorial representation of the actual 
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Figure 4: Procedure for the microinjection of mitochondrial suspension into One
applied to the holding pipette, attaches the embryo. Holding and injecting needle
the injecting needle 3; 3 to 9 O’clock insertion of the injecting needle, 4; Needl
end of embryo and injecting the mitochondrial suspension, 5; Carefully retrieve
injecting the mitochondrial suspension. 
 45Injecting NeedlHolding Needle                                3                                     
                            
                                   5                                     
 Cell Embryos. 1; Suction 
 labeled 2; Orientation of 
e pushed to the 9 O’clock 




Following the micromanipulation at the one-cell stage, embryos that survived the 
micromanipulation were washed through three sequential CZB droplets before incubating 




 in air. The embryos were 
later washed at the four cell stage and placed into fresh CZB medium droplets containing 






















2.5 MICROINJECTION OF MITOCHONDRIA INTO EMBRYOS 
-IDENTIFICATION OF HETEROGENEOUS MITOCHONDRIAL 
EMBRYOS: 
 
2.5.1 Designing the Nested PCR primers. 
 
To study the transfer of foreign mitochondria between two distinctly related sub-strains 
of mice both belonging to the Mus Musculus group, the C57/CBA F1 female mice and 
BALB/c female mice types were chosen. Using the mtDNA sequence differences 
provided 27, 28, 39, 8, 40, we were able to design the nested PCR primers for the COIII 
polymorphic site as described in figure 5 and 6 below. The COIII polymorphism is 
situated at the 9348bp site of the mtDNA sequence. The COIII polymorphism has been 
shown to be present exclusively in the C57BL/6J mtDNA and not in the BALB/cJ thus 
being able to differentiate between the two sub strains mtDNA’s and confirm the 
successful transfer of the ‘foreign’ mitochondria.27,28.  
 
Although the data reported by Bayona-Bafaluy et al; 2003 was for the C57BL/6J mtDNA 
and BALB/cJ mice, we would be theoretically able to amplify the mtDNA in our selected 
C57/CBA F1 and BALB/c mice, as the mtDNA is maternally inherited. The standard 
nomenclature universally used, requires the strain of the female breeder to be given first 
followed by the male breeder. i.e.; C57 x CBA F1 hybrid has a C57 strain female breeder 




and C57/CBA F1) and BALB (BALB/c and BALB/cJ) maternal breeder are therefore 
sufficient even though the paternal breeder may be different.  
 
The COIII polymorphic site at position 9348bp generates the recognition site which 
cleaves with the restriction enzyme AspI or its Isoschizomer PsyI only in the C57 
mitochondrial DNA. Since the COIII polymorphism is not present in the BALB mtDNA, 
upon digestion with AspI or its Isoschizomer PsyI, the BALB mtDNA should remain 
intact, thus allowing us to distinguish between the two sub-strains of mice.   
By amplifying the COIII polymorphism at site 9348bp, and using the restriction enzyme 
AspI/ PsyI to cleave the generated restriction site for AspI, we would be able to 
distinguishing between the C57 and BALB mitochondrial DNA and thus identify the 
embryos that successfully developed to the blastocyst stage that contained the injected 
BALB mtDNA (heterogeneous embryos). 
Since it is known that embryogenic mitochondria only resume transcription and gain 
ability following the blastocyst stage, each blastomere in the embryos is therefore entirely 
dependent on the energy produced from the oocyte-inherited mitochondria 44, 45, 46.  
Thus the dependence on maternal mitochondria suggests that the number of mitochondria 
found in the oocyte at the time of ovulation could be critical to the embryo development. 
Several studies have also shown that the mtDNA copy number in both mouse 47 and 
human 48,49 oocytes have a highly variable number of mtDNA molecules in individual 
oocytes, with the average copy number being ~ 100 000 for mouse and ~ 220 000 for 




number of mtDNA molecules. This variable could affect reproductive performance and 
embryo quality 47, 48, 49.  
 
Since the amplification of mtDNA from embryo cells of one cell to blastocyst stage is of 
small quantities, and furthermore, the injected mtDNA of the BALB mice is of minute 
quantities, nested PCR is required in order to successfully amplify the mtDNA of the two 
sub-strains successfully. The necessity of the nested PCR was tested initially by using 
only a first round PCR which did not successfully amplify the embryos mtDNA. Thus, 
we adapted the nested PCR technique with each round consisting of at least 40 cycles. 
The nested PCR was additionally necessary along with the PCR designed to include a 
high number of cycles, as the two mice types chosen were from similar sub-strains and 
the primers designed would amplify both the mtDNA’s. Only upon digestion with 
specific enzymes that would distinguish between the two DNA types, would we be able 
to differentiate between the two.  In order to design the nested PCR primers, the external 
primers were designed using the COIII polymorphic site27, 28, and the internal primers 
used were that of the ND3 C9461T polymorphism27, 28, 39, 8, and 40. 
 
However, since we should be able to clearly distinguish between the C57 and BALB 
mtDNA by studying the differences in the COIII polymorphism at site 9348bp for the 
two mice types, the sole purpose of the primers designed for the ND3 site was to provide 
a second reverse primer for the partial nested PCR. No restriction enzymes were used to 






Nested PCR primers were designed by aligning the two sequences obtained from 
GeneBank for the C57BL/6j mtDNA (GeneBank Reference: AJ512208) 8 and BALB/cj 
mtDNA (GeneBank Reference: AY172335)39.8.40, as shown in Figure 5.  
The sequences were aligned using a BLAST program provided online by the National 
Centre of Biotechnology Information (NCBI) 50 and nested PCR primers designed around 
the 9348bp COIII polymorphic site as shown in Figure 5 and 6 below.  
 
The partial nested PCR primers (1st base Pte Ltd, PCR grade, Singapore), were as follows 
(and as represented in figure 5 below.  
 
(First round PCR) External Primers; 
Position 9072-9093bp Fw, CGAAACCACATAAATCAAGCCC 
Position 9600-9623bp Rev, AAATTTTATTGAGAATGGTAGACG 
 
(Second Round PCR) Internal primers; 
Position 9072-9093bp Fw, CGAAACCACATAAATCAAGCCC 









Figure 5: Nested PCR designing. (Alignment of C57BL/6j mtDNA and Balb/cJ mtDNA for sequence differences). Representation of 
the First and Second PCR primers, along with COIII polymorphic site and cleavage site are shown by their respective arrows. 
 
C57 mtDNA : 9010  cagtacttctagcatcaggtgtttcaattacatgagctcatcatagccttatagaaggta 9069 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9010  cagtacttctagcatcaggtgtttcaattacatgagctcatcatagccttatagaaggta 9069 
 
                Forward Primer1&2 
                                                                          
C57 mtDNA : 9070  aacgaaaccacataaatcaagccctactaattaccattatactaggactttacttcacca 9129 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9070  aacgaaaccacataaatcaagccctactaattaccattatactaggactttacttcacca 9129 
                
                                                                          
C57 mtDNA : 9130  tcctccaagcttcagaatactttgaaacatcattctccatttcagatggtatctatggtt 9189 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9130  tcctccaagcttcagaatactttgaaacatcattctccatttcagatggtatctatggtt 9189 
 
                                                                          
C57 mtDNA : 9190  ctacattcttcatggctactggattccatggactccatgtaattattggatcaacattcc 9249 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9190  ctacattcttcatggctactggattccatggactccatgtaattattggatcaacattcc 9249 
 
                                                                          
C57 mtDNA : 9250  ttattgtttgcctactacgacaactaaaatttcacttcacatcaaaacatcacttcggat 9309 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9250  ttattgtttgcctactacgacaactaaaatttcacttcacatcaaaacatcacttcggat 9309 
                                             COIII polymorphic site  
                                                At position 9348  
                                                                ▼  ▼ 
           C57 mtDNA : 9310  ttgaagccgcagcatgatactgacattttgtagacgtagtctgacttttcctatacgtct 9369 
                  |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Balb mtDNA: 9310  ttgaagccgcagcatgatactgacattttgtagacgtaatctgacttttcctatacgtct 9369 
                                                     ▲  ▲                           
                                            PsyI Cleavage Site: 
                                           5'-G A C N^N N G T C-3' 







C57 mtDNA : 9370  ccatttattgatgaggatcttactcccttagtataattaatataactgacttccaattag 9429 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9370  ccatttattgatgaggatcttactcccttagtataattaatataactgacttccaattag 9429 
                     
                         Reverse Primer 2 
                                                                          
C57 mtDNA : 9430  tagattctgaataaacccagaagagagtaattaacctgtacactgttatcttcattaata 9489 
                  ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| 
Balb mtDNA: 9430  tagattctgaataaacccagaagagagtaatcaacctgtacactgttatcttcattaata 9489 
                                         
                                                                          
C57 mtDNA : 9490  ttttattatccctaacgctaattctagttgcattctgactcccccaaataaatctgtact 9549 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9490  ttttattatccctaacgctaattctagttgcattctgactcccccaaataaatctgtact 9549 
                                                              
                                                              Reverse Primer 1 
 
                                                                          
C57 mtDNA : 9550  cagaaaaagcaaatccatatgaatgcggattcgaccctacaagctctgcacgtctaccat 9609 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9550  cagaaaaagcaaatccatatgaatgcggattcgaccctacaagctctgcacgtctaccat 9609 
 
                                                                          
C57 mtDNA :9610  tctcaataaaatttttcttggtagcaattacatttctattatttgacctagaaattgctc 9669 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9610 tctcaataaaatttttcttggtagcaattacatttctattatttgacctagaaattgctc 9669 
 
                                                                          
C57 mtDNA : 9670  ttctacttccactaccatgagcaattcaaacaattaaaacctctactataataattatag 9729 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Balb mtDNA: 9670  ttctacttccactaccatgagcaattcaaacaattaaaacctctactataataattatag 9729 
 






2.5.2 Predicted Nested PCR products prior to and following Digestion with PsyI Restriction 
enzyme when the COIII polymorphism at site 9348bp is present 
 
Following the first round PCR, a predicted 551bp fragment would be generated. Upon 
digestion of this fragment, an expected 276bp and 275 bp fragments should theoretically 
result from the cleaving with the PsyI enzyme at the COIII polymorphic site. However, 
since these base pair fragments are of similar length, it would result in a higher intensity 
band at this position consisting of an overlap of both the 275bp and 276bp fragments as 
demonstrated in figure 6. 
From the second round PCR, an expected 384bp fragment would be generated which 
would cleave into two fragments of the 276bp and 108bp upon digestion with PsyI 
restriction enzyme at the COIII polymorphic site as demonstrated in Figure 6 below. 
It is important to note that analysis of the Second round PCR products would 
theoretically contain traces of the first round PCR that would be carried over. Therefore, 
the second round PCR products that would be digested would be an accumulation of both 
the first and second round products that would either be digested or not cleaved following 
digestion with PsyI depending on the presence of the PsyI cleavage site at the COIII 
polymorphism as described in figure 6 below. The virtual gel generated by interpolation 
in figure 6 below, was generated with the aid of the NEB Cutter 2.0 provided by New 
England Biolabs online 50. 
In the case of the mtDNA that is amplified that does not contain the COIII polymorphism 
at site 9348bp as has been reported in Balb mtDNA, the primers would amplify the 





fragment which would be identical to that of the C57 mtDNA where the polymorphic site 
as been reported to be preset. However, following digestion with the PsyI enzyme, the 
fragments would remain intact resulting in the first and second round PCR fragments of 
551bp and 384bp respectively. 
 
 
First Round PCR products                     Second Round PCR products 
Prior to and following digestion            Prior to and following digestion 
With PsyI enzyme                                  With PsyI enzyme 
 
                              
 
 
                      1a            1b          1c                             2a             2b          2c 
 
 
First Round PCR-Digested Fragments         Second Round PCR-Digested Fragments                               








# Ends  Coordinates  
 Length 
(bp)  
1   (Left End) PsyI  1-276  276 
2    PsyI – (Right End)   277-552  275 
# Ends  Coordinates  
 Length 
(bp)  
1  (Left End) PsyI    1-276  276 
2   PsyI  (Right End)  277-385  108 
 
Figure 6: The virtual gel generated by interpolation using NEB Cutter 2.0 50. First and Second 
Round PCR products generated if the COIII polymorphism is present, prior to and following the 
digestion With PsyI enzyme. 1; First round products, 2; Second round products, a; 100bp DNA 





2.5.3 Isolation of mtDNA from single embryos 
 
In previous experiments reported by Pinkert et al; 97, mitochondria were isolated from 
individual embryos followed by their mtDNA isolation, in order to detect the successful 
transfer of mitochondria into the embryo 4,5,42. However this protocol was reported by the 
author to be tedious by the researchers and a lot of difficulties were faced in the attempt 
to isolate the mitochondrial DNA from single embryos. Therefore, in our experiment, 
total DNA was isolated from the single embryos in order to avoid these complications 
and improve the efficiency. Additionally, the primers designed in this experiment where 
specific to the mtDNA and therefore would be specific to the mtDNA amplification.  
 
Total DNA was isolated using the method described by Q.H Wan et al 2003 51. Single 
embryos where placed in individual eppendorf tubes containing 20µl lysis buffer made 
up of 1 x PCR buffer containing 50mmol/l KCL and 10mmol/l Tris-HCL pH 8.4.The 
tubes were inspected under a microscope to confirm the successful transfer of the single 
embryo into each tube. The tubes were then incubated at 55°C for 30 minutes in a water 
bath, followed by an incubation of 100°C for 5 minutes. The tubes were then centrifuged 
at 1200 x g for 5 minutes. Without having to perform a phenol/chloroform extraction, the 
supernatant was placed in a clean PCR tube and used directly as the sample for nested 








2.5.4 Nested Polymerase Chain Reaction 
Nested PCR was carried out under the following conditions to increase the sensitivity of 
the assay; the first round PCR consisted of 40 cycles while the second round consisted of 
60 cycles. The conditions used for both rounds were at 95°C for 10 minutes (Pre-PCR 
activation step for Ampli Taq –Gold), followed by 30/60 cycles of 94°C for 45 seconds, 
58°C for 45seconds and 72°C for 45secs.This was followed by a 2 minutes at 72°C. 
From the first round reaction, 1µl of the product served as the DNA sample for the 
seconds round of PCR.  
For both rounds, the reaction mix consisted of 2.5µl PCR reaction buffer, 0.2mM each 
dNTP, 1.25U Ampli Taq-Gold DNA polymerase, and 0.4µM each primer, in a 25µl final 

















2.5.5 Digestion study using PsyI for the disruption at the COIII polymorphism at 
site 9348bp 
 
PsyI, a Commercial Isoschizomer that corresponds to the AspI was obtained from 
Fermentas due to the lack of availability of AspI at the time of the experiment. The 
cleavage sequences for PsyI and AspI restriction enzyme is described below. 
 
5'-G A C N^N N G T C-3' 
3'-C T G N N^N C A G-5'  
 
10U of the PsyI (Fermentas Inc. Hanover, MD, USA) concentrate was mixed with the 
provided 10X Buffer Tango. This was added to the 25µl of the PCR product and 
incubated at the optimal temperature of 37°C in a water bath overnight to ensure maximal 
digestion without producing any over digestion. 
The PCR products that were not subjected to digestion along with the digestion products 
were run on a 2% agarose gel made in TBE 1X, along side a 100bp GeneRuler 100bp 







































3.1 PREIMPLANTED EMBRYO VIABILITY AND DEVELOPMENT 
Following the recovery of embryos, morphology and viability were studied at various 
stages of the preimplanted embryo development in vitro. 
 
 
3.1.1 Cumulus Cell Radiance 
Before the removal of cumulus cells, embryos showing a good expansion and radiance of 
















Table 2: Embryo Development Rating (EDR) system: A Collective Staging of Viable embryo maturation after hCG injection 
 
 
  Time                 No. of          No. of arrested                                                                                                                            (%) a viable 
after hCG           oocytes              oocytes                                            Stage of maturation                                                        embryos 
   (hr)                  Viable 
                                                                              1 Cell        2 Cell      4 Cell       6-8 Cell       Morula       Blastocyst 
17-33                     260                     -                     260              0             0                0                  0                   0                           100% 
32-42                     251                    3                       6              251           0               0                   0                    0                           96.5% 
4 cell                     238                     5                      0                4             238             0                  0                    0                           91.5% 
6-8 cell                  220                     8                      0                0              5             220                0                    0                           84.6% 
Morula                  214                     2                      0                0              0               4                214                   0                           82.3% 
Blastocyst             212                     0                      0                0              0               0                  2                   212                          81.5% 
 






3.1.2 One cell Embryo Morphology  
Following the recovery of one cell embryos (17-33 hrs post hCG), ones that showed a 
first polar body and the extrusion of the second polar body were selected as viable 
embryos and were used in  further development studies. These embryos had a small 
perivitelline space. Embryos with a large perivitelline space were discarded at all stages. 
There were a total of 260 viable embryos that were selected following the embryo 




Figure 8: Zygote showing polar bodies 
and the male and female pronuclei prior 
to their fusion.  
Viable One Cell Embryos showed the 
first polar body present and or extrusion 














3.1.3 Two-Cell Embryo Morphology (32-38 hrs Post hCG) 
Newly formed two cell embryos with visible nucleoli (maternal and paternal) that had 
cleaved (32-42 hrs post hCG) and showed visible or degraded pronuclei (PN), were 
selected as shown in figure 9. The cleavage divisions in the two cell stage was equivalent 
(holoblastic cleavage), resulting in two blastomeres of equal size. 














Viable nucleoli (maternal and paternal) contained in the nucleus 
 
Figure 9: Viable two cell embryos with visible nuclei (32-42 hrs post hCG) 1, 2 and 3; Two Cell 






The perivitelline spaces were small and all viable embryos showed healthy cytoplasm. 
All embryos selected had an intact zona pellucida. The cell divisions occurred within the 
zona pellucida with a sequential reduction in cytoplasmic volume. 
There were a total of 251 viable two cell embryos that showed healthy morphology. 
Three embryos had arrested in development and showed poor embryo morphology. Six 
embryos showed a slow rate of development and were still at the one cell stage. All 
arrested and one cell embryos were discarded. A total percentage of 96.5% two cell 




















3.1.4 Four-Cell Embryo Morphology 
 
 
The cleavage divisions in the four cell stage were equivalent (holoblastic cleavage) as 
seen in the two cell stage embryos. The resulting cleavage gave rise to four blastomeres 
of equal size. The perivitelline spaces were small and all cells showed a healthy 
cytoplasm. An intact zona pellucida with no damage was observed. 
A total of 238 four cell embryos showed successful development. Five embryos had 
arrested showing poor embryo morphology. All arrested embryos showed blastomeres 
that were of different sizes and poor cytoplasm. Four embryos were at the two cell stage. 
All arrested and two cell embryos were discarded resulting in a 91.5% viability of total 
four cell embryos (Table 2). 
 
 















3.1.5 Six to Eight-Cell Embryo Morphology 
 
At the six to eight cell stages, an intact zona pellucida with no damage was observed 




Figure 11:  Eight to Sixteen Cell Embryos Six 







A total of 220 embryos had collectively grown to the 6-8 cell stage. Eight embryos had 
arrested in development and showed poor cytoplasm with large perivitelline spaces. Five 
embryos showed slow development and were at the four cell stage. All arrested and four 
cell embryos were discarded and a total of 84.6% embryos viable at the 6-8 cell stage 








3.1.6 Early or late Morula (Compacting or compacted 8-16 cell Embryos) 
Embryos at the morula stages showed a significant change known as compaction. Some 
embryos were at the compacting stage where the blastomeres of the 8-16 cell embryos 
were starting to closely pack together (fig 12 and 13). The morula embryos additionally 
showed cell flattening (uvomorulin) with gap junction formations. This was the first 
morphological stage showing cell differentiation. The zona pellucida in all embryos 
remained intact and healthy. A collective view of the early and late morula embryos 
obtained is shown in fig 14. Both early and late stage morula embryos were selected for 
further incubation and considered viable.  
 
         
 
Figure 12: Compacting Eight to Sixteen cell embryo 





Figure 13: Compacted morula embryos. Nuclei in 








Figure 14: A collective comparison of early and late morula embryos. 
 
A total of 214 embryos had successfully grown to the morula stage. A collective 82.3% 
viable compacting and compacted embryos were considered as viable and further 
incubated. Two embryos arrested in development and four were still at the 6-8 cell stage. 










3.1.7 Early and Late Blastocyst Embryos 
Viable blastocysts consisted of the inner cell mass (ICM), the blastocoel (a hollow cavity) 
and the trophectoderm (trophoblasts) which are the cells surrounding the blastocoel. 
There was a tight junction formation seen between the trophoderm. The different stages 
of the blastocyst phase noted were the early (fig 15) and late or fully expanded 
blastocysts (fig 16). A collective representation of both early and  late/fully expanded 
blastocysts is presented in figure 17.This was followed by the blastocysts growing to the 
hatching or hatched blastocysts as shown in figure 18 where the zona pellucida ruptured. 
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FIGURE 17: A collective comparison of the Early and late/fully expanded 









A total of 212 embryos had successfully grown to the blastocyst stage. A total 81.5% 
early and late blastocysts embryo were calculated as viable. No embryos arrested in 
development while two embryos showed slow development and were at the morula cell 
stage. All morula embryos were discarded. 81.5% embryos were thus considered to be 
viable and had successfully grown to the blastocyst stage in vitro (Table 2). 

























The hatching and hatched blastocysts showed a rupture of the zona pellucida and the 
blastocoel contents were released from the embryo. The viability of the hatched 
blastocysts was not recorded as embryos at the blastocyst stage are the ideal stage in 
development for re-implantation into the pseudo-pregnant females. They were studied for 
the sole purpose of understanding the morphology of the embryos post-blastocyst. They 
were not incubated for further culturing. 
A visual comparison of the various stages of the mouse preimplanted embryos can be 
seen in figure 19 below, where morphological changes can be compared between all the 




































                                                                                                    
 




















Figure 19: A Comparative Morphology of C57/CBA Mouse Embryo Development in vitro.1; 
One cell embryo, 2; Two cell embryo (-PB), 3; Two cell embryo (+PB), 4; Four cell embryo, 5; 6 
to 8 Cell embryo 6; 8 to 16 cell compacting embryo, 7 compacted morula, 8; early blastocyst, 9; 







3.2 Mitochondrial Distribution in the Preimplanted Mouse Embryo 
3.2.1 Embryo Assessment and Mitochondrial Distribution in the C57/CBA Embryos 
The results obtained are a cumulative number of the embryos studied over the course of 
studying the mitochondrial distribution in normal embryo development. All six control 
embryos per developmental stage were not stained with any dye, but subjected to the 
same procedures as the experimental embryos. These control embryos did not display any 
fluorescence of at any wavelength. 
Mitochondrial distribution (mitochondria stained in green) reported in this study was 














    Perinuclear 
 
Figure 20: Characterization of distinct mitochondrial (demonstrated in green) distribution 
patterns. Homogenous: a uniform distribution throughout the embryo, Aggregated: a granular 
distribution, Perinuclear: clustering around the pronuclei, Cortical: accumulation close to the 
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           A                                 B                        C 
Figure 23: A comparative representation of the double staining with both Green FM and 
Rhodamine 123 dyes. A: confocal   B: epifluorescence C: Normal. 1: Green FM, 2: Rhodamine 
123, 3: Double staining with Green FM and Rhodamine123      
 
 
To compare the distribution in active and non-active mitochondria, Rhodamine 123 and 
Green Fm dyes were used in a double staining experiment as seen in figure 23. In 
comparison, the same embryos were double stained with Mitotracker green fm that 
accumulates into both active and non-active mitochondria. The intensity in rhodamine 
123 staining as seen in B2 was similar to the intensity seen for mitotracker green FM 
shown in A1. The mitochondrial distribution patterns seen for both dyes were 
homogenously distributed throughout the embryos for both dyes. When compared 





perinuclear accumulation seen in the green Fm compared to the rhodamine 123 staining 
as can be seen in A3 and B3. The polar bodies similarly showed a slightly higher 
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Figure 25: Double staining using Green FM and Rhodamine 123 dyes. A: Normal-Green FM 
staining: epifluorescence double staining, C: epifluorescence Green FM, D: epifluorescence 
Rhodamine 123 staining. Pink arrows indicate Polar body location. 
 
 
In a comparative study on  the distribution of active and non-active mitochondria, the 
intensity in rhodamine 123 staining was similar to the intensity seen for mitotracker green 
FM for all the 25 embryos studied. The mitochondrial distribution patterns seen for both 
dyes was homogenously distributed in both blastomeres. In embryos where polar bodies 
remained intact, polar bodies were staining with similar intensities for both dyes with the 
green FM dye showing a slightly stronger polar body staining. When compared visually, 
both dyes produced almost similar intensities with similar distribution patterns in all 
embryos at various planes studied. However, there was a stronger perinuclear 
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3.2.9 Late Morula embryos 
In the late morula embryos, there was an aggregated and cortical pattern of mitochondrial 
distribution seen in all embryos studied. Mitochondrial distribution in the late morula 
stage embryos was more concentrated in the cortical regions of the embryo. There was 
very little mitochondrial presence seen in the centre of the embryos showing a scattered 
mitochondrial distribution. Figure 28-A shows the normal morula, while Bi, ii and iii 
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Figure 28: Morula embryos stained with Green FM. A: Normal, Bi, Bii and Biii epifluorescence 










3.2.10 Blastocyst embryos 
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Figure 29: Blastocyst staining with Green FM at two early blastocyst stages. A: Normal, B: 






Mitochondria in early blastocysts showed a dramatic shift in mitochondrial distribution to 
the cortical distribution pattern. The mitochondrial staining was seen in the trophoderm 
and inner cell mass with no staining noticed in the hollow blastocoel as seen in (Aii) and 
(Bii).  
The staining intensities noticed in the trophoderm and inner cell mass changed as the 
blastocyst progressed in its development from the early (Ci) to the late blastocyst (Cii). In 
the earlier blastocysts, the inner cell mass staining was diffused (Ci).  In the later 
blastocysts, the trophoderm clearly showed a higher intensity of staining and the inner 























































Figure 30: Late blastocysts stained with Green FM. A: Normal, B: confocal, C i, ii and iii 
epifluorescence at three various planes. 
As the blastocyst went through further development into the late blastocyst stages, the 
mitochondrial distribution showed a shift to and tight perinuclear position and a slow 
shift from the trophoderm as seen in C i, ii and iii epifluorescence of the same late 





3.2.12 A collective representation of mouse embryos stained with Green FM. 

























Figure 31: A collective representation of mouse embryos stained with Green FM. A: One cell, B: 
Two cell with polar body intact, Bii; Two cell embryo with polar body degraded, C: Four cell, D: 




A visual comparison of the various stages of the mouse preimplanted embryos can be 
compared to see the mitochondrial distribution and relocation patterns as shown above in 
figure 31. The one cell embryos to the 6-8 cell embryos, all showed homogenous 
distribution in the blastomeres with a perinuclear halo. In the morula and blastocyst 
stages, a significant change in mitochondrial distribution was first seen. There was a shift 





cortex in the blastocyst embryos. The mitochondria were later seen to shift in the 


























3.3 Microinjection of mitochondria into embryos
3.3.1 Assessment of Embryo development after microinjection 
Embryos were assessed at each cell stage of development. The criteria used for normal 
embryo development was as described earlier. The results shown in table 3 below are a 
cumulative number of the embryos studied over the course of performing the 















Table 3: Staging of Viable oocyte maturation after hCG injection 
 
 
Time                   No. of viable      No. of arrested                                                                                                                         (%) a viable 
After hCG           oocytes              oocytes                                            Stage of maturation                                                           embryos 
(Hr)           
                                                                              1 Cell        2 Cell      4 Cell       6-8 Cell       Morula       Blastocyst 
                                                                            (Day 0.5) 
17-33                         120                     -                 120              0             0                 0                  0                   0                           100% 
32-42                         115                     2                  3              115            0                0                  0                   0                           95.8% 
4 cell                          109                    4                   0                2             109             0                  0                   0                           90.8% 
6-8 cell                       106                    1                  0                0               2             106                0                   0                           88.3% 
Morula                       104                    2                   0                0              0                0                104                 0                           86.6% 
Blastocyst                   104                   0                   0                0              0                0                  0                 104                         86.6% 
 





3.3.1.1 Embryo Morphology following the one cell embryo micromanipulation
 
                                                                                     
 1. One cell (Day 0.5)               2.Two cell (+ PB)                           3. Four cell     
 
                    
        4. Eight cell                        5.Early morula                      6.Late blastocyst        
                                                     (Compacting)       
 
Figure 32: Comparative Embryo Morphology of the various embryo developmental stages 
following the one cell microinjection of Balb mitochondrial suspension. 
 
 
3.3.1.2 Control embryos 
Control embryos that did not undergo any micromanipulation showed normal embryo 
morphology throughout their development to the blastocyst stage. Control embryos that 
were injected with a blank suspension (mitochondrial suspension buffer) did not show 
any significant morphological difference in comparison to the normal embryo 
development as discussed in chapter 2. There were two embryos that were ruptured 
during the microinjection procedure which is anticipated while performing 







3.3.1.3 Day 0.5 One cell embryos 
Following the microinjection of the Balb mitochondrial suspension into one cell embryos, 
the morphology was studied at day 0.5as reported in figure 32 and table 3. A total of 182 
embryos were injected with the Balb mitochondrial suspension out of which 120 survived 
the micromanipulation procedure without rupturing. Upon selecting the viable embryos 
for further culture on day 0.5, all 120 embryos showed a healthy morphology on day 0.5 
(4-5 hours post micromanipulation).  
 
3.3.1.4 Two cell embryos 
Embryos with visible nucleoli (maternal and paternal) and embryos that showed visible 
or degraded polar bodies were selected. A total of 115 embryos were viable at the two 
cell stage. Two embryos had arrested or showed uneven blastomeres with poor 
cytoplasm. Three embryos were at the once cell stage, thus showing a slow 
developmental rate and were discarded. All 115 two cell embryos with or without a polar 
body were further incubated (refer to figure 32 and table 3). 
 
3.3.1.5 Four-Cell Embryo Morphology 
The cleavage divisions in the four cell stage were equivalent (holoblastic cleavage). A 
total of 90.8% embryos that under went micromanipulation were considered viable at the 
four cell stage with 4 embryos arrested. The two embryos that remained at the two cell 
stage along with arrested embryos were discarded and viable embryos further cultured 






3.3.1.6 Six to Eight-Cell Embryo Morphology 
A total of 88.3% embryos that under went micromanipulation were viable at the six to 
eight cell stages (refer to figure 32 and table 3). One embryo that was considered 
unhealthy, along with two embryos that remained at the four cell stage were discarded. 
 
3.3.1.7 Early or late Morula (Compacting and compacted 8-16 cell Embryos) 
Embryos at the 8-16 cell embryos showed a significant change or compaction (refer to 
figure 32 and table 3). A total of 104 embryos had successfully grown to the morula 
stage. These included a collection of both compacting and compacted embryos. Only two 
embryos that remained at the 6-8 cell stage and showed no signs of compaction were 
discarded and the rest cultured for further analysis. The total percentage of morula 
embryos that survived were 86.6% of the original one cell embryos chosen. 
 
 
3.3.1.8 Early and Late Blastocyst Embryos 
Viable blastocysts consisted of the inner cell mass (ICM), the blastocoel (a hollow cavity) 
and the trophectoderm (refer to figure 32 and table 3). A total of 104 embryos had 
successfully grown to the blastocyst stage from the one cell viable embryos. This was an 










3.3.2 Microinjection of mitochondria into embryos: Mitochondrial Preparation: 
3.3.2.1 Mitochondrial Integrity Study using JC-1 Dye 
The mitochondrial suspension was diluted with storage buffer to a 1mg concentration. 
This was then diluted to a 5µg, 20µg and 40µg protein concentrations to perform the JC-1 
assay at increasing mitochondrial protein concentrations. The fluorescence was read 
using a spectro-flourometer set at an excitation wavelength of 490 nm and the slit set at 5 
nm. The emission wavelength was set at 590 nm and the slit at 7.2 nm. 
 
The fluorescence was calculated per mg mitochondrial protein (FLU/mgP) using the 
following formula. The data was then plotted for a linear representation of the JC-1 
uptake versus amount of mitochondria. 
FLU/mgP = (∆FL) x dil/ V x C 
          FLU= fluorescence units 
          mgP= milligram protein 
            ∆FL = FLsample - FLblank 
            dil = dilution factor to prepare 1 mg/ml suspension  
             C = mgP/ml 










Table 4: Sample Preparations for JC-1 Assay 
Sample JC-1 stain Storage Buffer Sample  FLU/mgP 
Blank 2µl 100µl (No   
Protein)
 
       0 
2µl 
 
100µl minus 5ug    5µg       48 
2µl 
 
























Figure 33: Linearity of JC-1 uptake by various mitochondrial concentrations 
 
From the linear representation of the data plotted in table 4, figure 33 showed a linear 
graph of the JC-1 uptake. The mitochondrial protein concentration versus the 
fluorescence showed that the 5, 20 and 40 µg protein concentrations exhibited an 





3.3.3 Microinjection of mitochondria into embryos: Identification of   heterogeneous 
embryos 
3.3.3.1 A comparison of the C57 mtDNA liver and BALB liver mtDNA 
Liver samples of C57 mtDNA and BALB mtDNA were amplified with first round 
primers and digested with the restriction enzyme PsyI, to test for the COIII polymorphic 
site at position 9348bp. First round PCR products (Undigested) were visualized along 
side their digestion products as seen in Figure 34 below. The negative control PCR 
product containing no DNA did not show any fragments generated prior to (Lane 2) and 
following digestion (Lane 3). The PCR products that were not subjected to digestion for 
the C57mtDNA (Lane 4) and BALB mtDNA (Lane 6) generated a 551bp fragment for 
the first round. Following the digestion with the PsyI enzyme, the C57 digested samples 
produced a 275/276 bp fragment (Lane 5) of equal intensity to that of the undigested 
fragment in lane 4. However, the digestion product for the BALB mtDNA was a clear un-
cleaved or intact 551bp fragment (Lane 7).  
        
            7                       6                     5                      4                       3                  2                    1 
Figure 34: Lane 1: 100bp DNA Ladder, Lane 2: Negative control PCR product (no DNA)-
Undigested, Lane 3: negative control PCR product (no DNA)-Digested, Lane 4: C57 mtDNA 
from Liver PCR product-Undigested, Lane 5: C57 mtDNA from Liver PCR product-Digested, 







3.3.3.2 A Comparison of the liver mitochondrial DNA samples isolated from the C57 
and Balb livers and the heterogeneous embryos created: 
Second Round PCR products prior to digestion with PsyI  
In the comparative study of the liver mitochondrial DNA samples isolated from the C57 
and Balb liver samples to the heterogeneous embryos created, second round PCR 
products that had not been subjected to the PsyI enzyme digestion were initially 
compared as illustrated in figure 35. In the control group where no DNA was added, there 
was no DNA amplification seen (Lane 2). Lanes 3-16 all showed the amplification of 
three fragments at 384bp, 551bp and >1000bp. The intensities of the 384bp fragments 
were stronger than the 551bp fragments as seen in lanes 3-16.   
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Figure 35: Lane 1: 100 bp DNA ladder, Lane 2: Negative control (no DNA/liver sample/embryo), 
Lane 3: C57 Liver mtDNA, Lane 4: BALB Liver mtDNA, Lane 5-7: Day 0.5 not injected, Lane 
8-10: Day 0.5 injected, Lane 11-13: blastocyst embryo not injected, Lane 14-16: blastocyst 









Second Round PCR products following digestion with PsyI  
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Figure 36: Lane 16; 100 bp DNA ladder, Lane 1; Negative control (no DNA/liver 
sample/embryo), Lane 2; C57 Liver mtDNA, Lane 3; BALB Liver mtDNA, Lane 4-6; Day 0.5 
not injected, Lane 7-9; Day 0.5 injected, Lane 10-12; blastocyst embryo not injected, Lane 13-15; 
blastocyst embryo injected  
 
In Figure 36, second round PCR products were digested over night with the PsyI enzyme. 
The negative control did not generate any fragments after digestion (lane 1). The C57 
mtDNA liver sample in lane 2 produced two fragments at ~108bp and ~276/275 bp. The 
108bp fragments were of weaker intensities in comparison to the 276/275 bp fragment.  
In lane 3 containing the BALB liver mtDNA sample, 384bp and 551bp fragments were 
seen with the 384bp fragment showing a higher intensity.  
In lanes 4-6, the day 0.5 embryos that were not subjected to microinjection with BALB 
liver mtDNA showed 108bp and 276/275 bp fragments. The 108bp fragments were of 
weaker intensities in comparison to that of the 276/275 bp fragment.   
In lanes 7-9, with embryos at day 0.5 that were injected with BALB mtDNA, four 





The intensity of the 276/275 bp fragments were clearly stronger than the rest, while the 
intensity of the 108bp fragments was the weakest. 
Lanes 10-12 contained single control blastocysts each that were not injected with BALB 
liver mtDNA at the one cell stage and cultured to the blastocyst stage under the same 
conditions. Following digestion, two fragments of 108bp and 276/275 bp were seen. The 
~276bp fragments showed a higher intensity of about two to three fold increments.  
Lanes 13-15 contained single blastocyst embryos each that were injected with BALB 
liver suspension at the one cell stage and incubated to the blastocyst stage. Following 
digestion, the results showed four fragments at 108bp, 276/275 bp, 385bp and 551bp. The 


















3.3.3.3 Determining the concentration ratios of the two mtDNA sub-strains in the 
heterogeneous embryos produced.  
 
To study the fate of the injected mitochondria and the native mitochondria in the embryos 
generated, a comparative study of a range of concentrations of both C57 and BALB 
mtDNA from liver samples were compared to the embryos that had been injected with 
BALB mitochondria cultured to the blastocyst stage as shown below. The results were as 
shown in figure 37 below. 
 
First Round PCR products-Undigested 
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Figure 37: Lane 1; 100bp DNA Ladder, Lane 2; Negative control (no DNA) Lane 3- 7: C57 
mtDNA from liver samples at decreasing concentrations Lane 3; 1ng C57 mtDNA. Lane 4; 700 
pg C57 mtDNA, Lane5; 100pg C57mtDNA, Lane6; 70pg C57mtDNA, Lane7; 7 pg C57mtDNA, 
Lane 8 -10 BALB Liver mtDNA from liver samples with decreasing the concentrations, Lane 8; 
1ng Balb mtDNA, Lane 9; 700pg Balb mtDNA, Lane 10; 7pg Balb mtDNA, Lane 11-15: C57 
Single embryos injected with BALB mitochondria and cultures to various stages. Lane 11: one 
cell embryo, Lane 12: two cell embryo, Lane 13: four cell embryo, Lane 14: morula, Lane: 15 








 The first round PCR products of the negative control with no mtDNA from liver or 
embryos did not amplify any DNA. Lanes 3-7, (Lane 3: 1ng C57 mtDNA, Lane 4: 700 pg 
C57 mtDNA, Lane5: 100pg C57mtDNA, Lane6: 70pg C57mtDNA and Lane7: 7 pg 
C57mtDNA) contained a decreasing concentration of C57 liver mtDNA samples. Lane 3, 
5, 6 and 7 showed a decreasing intensity of the 551bp fragments generated with lane 3 
being the highest intensity and lane 7, the lowest. However, there were no DNA 
fragments amplified in lane 4 containing the 700 pg of C57 mtDNA from the first round 
of PCR.  
Lanes 8-10 were of decreasing concentrations of BALB mtDNA from liver samples 
(Lane 8; 1ng Balb mtDNA, Lane 9; 700pg Balb mtDNA, Lane 10; 7pg Balb mtDNA). 
Lanes 8 and 9 showed a 551bp fragment with a higher intensity in lane 9. The BALB 
mtDNA at the 7pg concentration however did not produce any visible fragments.  
Lanes 11 to 15 were of the various embryonic stages of development that were injected 
with BALB Mitochondria at the one cell stage. All embryos at the various stages 
produced a first round PCR product of 551bp. The intensity of the embryo in lane 12 was 











Second Round PCR products-Undigested  
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Figure 38:  Lane 1; 100bp DNA Ladder, Lane 2; Negative control (no DNA) Lane 3 to 7: C57 
mtDNA from liver samples at decreasing concentrations Lane 3; 1ng C57 mtDNA. Lane 4; 700 
pg C57 mtDNA, Lane5; 100pg C57mtDNA, Lane6; 70pg C57mtDNA, Lane7; 7 pg C57mtDNA, 
Lane 8 to 10 BALB Liver mtDNA from liver samples with decreasing the concentrations, Lane 8; 
1ng Balb mtDNA, Lane 9; 700pg Balb mtDNA, Lane 10; 7pg Balb mtDNA, Lane 11-15: C57 
Single embryos injected with BALB mitochondria and cultures to various stages. Lane 11: one 
cell embryo, Lane 12: two cell embryo, Lane 13: four cell embryo, Lane 14: morula, Lane: 15 
blastocyst embryo.  
 
Results from the second round PCR products prior to digestion for studying the fate of 
the injected mitochondria and the native mitochondria in the embryos generated, are as 
shown in figure 38 above. For the second round PCR products, the negative control did 
not produce any fragments. The C57 mtDNA from the liver samples in lanes 3- 5 
produced the second round PCR 384bp fragment along with a weaker intensity 551bp 
fragment in each lane. However, in lane 7, there was a single 384bp fragment. Lanes 8-10 
for the Balb mtDNA produced the 384bp fragment in lanes 8 and 9 along with its weaker 
551bp fragment. However lane 10 containing only 7pg, did not generate any visible 
fragments of either size. All embryos at the various stages in lanes 11-15 produced the 





intensity. In all mtDNA samples studied here, there was no presence of a >1000bp 
fragment. 
Second Round Digested 
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Figure 39:  Lane 1; 100bp DNA Ladder, Lane 2; Negative control (no DNA) Lane 3 to 7: C57 mtDNA 
from liver samples at decreasing concentrations Lane 3; 1ng C57 mtDNA. Lane 4; 700 pg C57 mtDNA, 
Lane5; 100pg C57mtDNA, Lane6; 70pg C57mtDNA, Lane7; 7 pg C57mtDNA, Lane 8 to 10 BALB Liver 
mtDNA from liver samples with decreasing the concentrations, Lane 8; 1ng Balb mtDNA, Lane 9; 700pg 
Balb mtDNA, Lane 10; 7pg Balb mtDNA, Lane 11-15: C57 Single embryos injected with BALB 
mitochondria and cultures to various stages. Lane 11: one cell embryo, Lane 12: two cell embryo, Lane 13: 
four cell embryo, Lane 14: morula, Lane:15 blastocyst embryo.  
 
Following digestion of the second round PCR products with PsyI enzyme as seen in 
figure 39, the negative control remained consistent in its results with no fragment 
generated. The C57 mtDNA liver fragments generated two fragments (Lanes 3-7). A 
higher intensity 276/275 bp fragment and a 108bp fragment of weaker intensity.  
The Balb mtDNA liver samples in lanes 8 and 9 showed intact 384bp and 551 bp 
fragments. The Balb mtDNA of the lowest concentration in lane 10 however did not 
produce any fragments after the digestion with PsyI. In lanes 11-15, all embryos (one, 
two, four, morula and blastocyst embryos) showed four fragments each, following their 
digestion. A 107bp, 276/275 bp, 384bp and 551bp fragment were seen in each lane of 





visually denser. This was followed by a weaker 384bp fragment and a 551bp fragment 
showing a very weak intensity in each embryo.  
 
 
3.3.3.4 Heterogeneous mitochondrial DNA in C57 embryos at various embryonic 
stages injected with Balb mitochondria.  
 
Second Round Nested PCR products-Undigested 
Second round control samples did not amplify any fragments (Lane 2). All embryos at 
various developmental stages showed similar fragments generated prior to digestion. In 
Lanes 3-13, there were two fragments produced. A 384bp and a 551bp fragment where 
the intensities of the 384bp fragments were higher than their corresponding 551bp 
fragments were seen for all 3-13 lanes. 
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Figure 40: Lane 1: 100bp ladder, Lane 2: negative control (no mitochondria or embryo), Lane 3-
5: day 0.5 C57 embryo injected with BLAB mitochondria, Lane 6-8, Two cell C57 embryo 
injected with BALB mitochondria, Lane 9-11: Morula embryos injected with BALB 







Second Round PCR products following digestion with PsyI  
Following digestion, control samples did not amplify any fragments (Lane 2). Second 
round PCR products of the embryos injected with BALB liver mitochondria that were 
further digested overnight with PsyI, showed digestion products in all embryos (lanes 3-
13).The different samples were, Day 0.5 embryos that had been injected with BALB 
mtDNA (lanes 3-5), two cell embryos injected at one cell stage and incubated (Lanes 6-
8), morula embryos that were injected with BALB mtDNA at one cell stage and 
incubated (Lanes 9-11) and blastocyst embryos (Lanes 12-13)  
 In Lanes 3-13, there were four fragments produced in all samples. A 108bp, 276/275 bp, 
384bp and 551bp fragments were seen for each embryo digested. The intensity of the 
276/275 bp fragment were clearly stronger than the rest of the fragments in all embryos 
with a weakest intensity seen in the 551bp fragments. The fragments seen in lane 3 were 
weaker in comparison to the rest of the lanes. 
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Figure 41: Lane 1: 100bp ladder, Lane 2: negative control (no mitochondria or embryo), Lane 3-
5: day 0.5 C57 embryo injected with BLAB mitochondria, Lane 6-8, Two cell C57 embryo 
injected with BALB mitochondria, Lane 9-11: Morula embryos injected with BALB 































In the studies carried out earlier on the transfer, detection and fate of the injected 
mitochondria into the embryos of C57 mice, the results showed a successful transfer of 
the Balb mtDNA into the embryos. The detection method used here was differentiating 
and sensitive enough for both mtDNA types and the foreign mtDNA was retained in the 
heterogeneous embryos rather than being sequentially eliminated over the development 
time. The findings for the various studies have been discussed in detail in this chapter. 
 
In the study conducted on the morphology of the mouse embryo development in vitro, the 
results show that a total percentage of 81.5% of the embryos that were recovered had 
successfully grown to the blastocyst stage using the techniques and media used in the 
experiments conducted and was thus used as a good reference point for all further embryo 
isolation and quality control in all further studies used in our experiments. The 
morphological development of the embryos reported here are consistent with findings of 
previous work carried out on the C57 mice pre-implanted embryos and helped form good 
reference point for ‘normal’ embryo development following the micromanipulation of the 
embryos.  
At the four cell stage, viable embryos were transferred into fresh droplets of CZB 
medium with an addition of 0.55M glucose as it has been reported that the 
preimplantation embryos experience a striking change in energy preference at this stage 
52, 53, 54. At the four cell stage, there were a total of 4 embryos that had arrested in 
development and two embryos that remained dormant at the 2-cell stage. This may be 






As seen in the 1-8 cell embryos, all viable embryos showed cleavage divisions where all 
cells replicated with equivalent cleavages (holoblastic cleavage), with an intact zona 
pellucida. The perivitelline spaces were small and all embryos selected as viable had 
reached their developmental stages at the expected times, which are consistent with 
previous studies reported. At the early and late stage morula, a significant change in 
development first occurred where cell flattening (uvomorulin) was seen along with gap 
junction formations. The morula embryos studied resembled ‘mulberry’ shapes as termed 
by its Latin name ‘morula’. In the early and late blastocysts studied, two distinct cell 
types were noted. The inner cell mass (ICM) cells which are known to go on to form the 
embryo proper and the trophodermal cells were seen. The major feature of a hollow 
cavity called the blastocoel was consistently seen in all blastocysts. The layer of cells 
around the blastocoel, known as the trophoblast (or trophoderm) which is known to be 
involved in the implantation of the blastocyst into the uterus and eventually contribute to 
the placenta and the extra-embryonic membranes was also consistently seen with tight 
junctions between the trophoderm33.  
 
By using mitochondrial markers selective for active and non-active mitochondria, I was 
able to successfully study the mitochondrial distribution and relocation patterns in 
preimplantation embryos in vitro. This provides a well established methodology to be 
used in further studies in creating mouse models and would be essential in further 
determining the fate of the activity of the native on the foreign mitochondria and vice a 






From the one cell embryos to the 6-8 cell embryos, all showed similar trends of 
homogenous distribution in the blastomeres with a perinuclear halo exhibiting nuclear 
mitochondrial cluttering. In the one and two cell embryos where polar bodies were intact, 
all polar bodies were stained with the mitotracker green dye and the rhodamine 123 dye, 
showing the presence of mitochondria through out the polar bodies. The mitochondria 
were not present in the pronuclei of the embryos, but were shown surrounding the 
pronuclei in the one to eight cell embryos. However, in the double staining studies using 
green FM and rhodamine 123, there was a stronger polar body accumulation seen in the 
green Fm compared to the rhodamine 123 staining in both one and two cell embryos. 
This could be due to an accumulation of more non active mitochondria present in the 
polar bodies.  
In all morula and blastocyst stages, a significant change in mitochondrial distribution was 
first seen. The morula stages showed an aggregated and more cortical mitochondrial 
distribution while the blastocysts showed a cortical distribution in the trophoderm. The 
blastocoel did not show any mitochondrial presence in all blastocysts. This shows that 
there is a shift in the mitochondrial distribution as the embryos developed from the 
morula to blastocyst stages. The mitochondria were shown to relocate to the cortical 
region of the embryos where the trophoderm was present.  
Results on the mitochondrial distribution patterns seen in the pre-implanted embryos 
presented in this thesis are consistent with findings of previous work carried out on the 
C57 mice pre-implanted embryos 55. These results also indicate good development in the 
embryos that would have a potentially high implantation rate 55. From previous reports on 






believed to be almost uniform, but when energy requirements are unevenly distributed, 
mitochondria tends to aggregate at sites of the energy demand 30, 63, and 64. It has also been 
reported that mitochondrial relocation and distribution vary with changes in cell function, 
such as metabolic changes and during cell proliferation and differentiation 30, 65, 66, 67, 68, 69, 
70, 71 and 72.  Therefore, these results show the relocation of mitochondria in the embryonic 
stages in accordance with the energy demands within the embryos. 
One of the limitations in this method of studying the mitochondrial distribution using 
commercially available dyes selective to mitochondria is that the embryos that have been 
stained with the dyes cannot themselves be re-implanted into the pseudo pregnant female 
due to the toxicity of all currently available commercially dyes. Thus, the one cell 
embryos cannot be stained and left to incubate even to the blastocyst stage.  
This method would therefore be good in providing initial insights on the effects of the 
foreign mitochondria on the native mitochondria in creating mouse models to study 
mitochondrial diseases. However, these embryos cannot themselves then be re-implanted 
into pseudo-pregnant females. This could in addition be replicated when studying the 
effects of the mitochondrial mutations that are ‘altered’ prior to their injection into 
embryo cells in vitro in future studies. We would thus begin to determine the therapeutic 
effects of these ‘altered’ mitochondria at the embryonic level of development. 
 
 
Mitochondrial isolation and detection techniques presented here are efficient and 
improved for the microinjection of mitochondria into the embryos so as to have a high 






is important in the successful transfer of mitochondria into the embryos as only minute 
volumes can be injected into the embryos. A high purity suspension with a higher number 
of intact mitochondria therefore increased the chances of intact mitochondria being 
introduced into the embryos in the small volumes injected. 
The JC-1 uptake for the increasing concentrations of mitochondria showed a clear 
increase in fluorescence (FLU/mgP). This was represented in the linear plot achieved. 
Active mitochondria are known to display a high ∆Ψm, while inactive or dead 
mitochondria display a low ∆Ψm . In this way I was able to ensure that all 
mitochondrial suspensions used for the injection into embryos were of high integrity and 
intact at the time of performing the micromanipulation.
41
 
In addition, I also successfully adapted a simple and improved methodology for the 
detection of successful transfer of mitochondria into the embryos 4, 5, 42. Total DNA that 
was isolated from the single embryos was clearly successful and the mtDNA was 




Following the microinjection of Balb mitochondrial suspension at the one cell stage, 
morphology studies of the embryos all showed consistent and similar trends to that of the 
earlier study of normal embryos that were not subjected to micro-manipulation and 
furthermore, indicate good development in the embryos that would have a potentially 






A total of 182 embryos were injected with the Balb mitochondrial suspension and 120 
embryos were chosen as viable on day 0.5. This reduction in number could have been due 
to the shock affecting the embryos during micromanipulation along with the injection of 
a foreign suspension, causing them to rupture. However, there is an anticipated chance of 
some embryos to rupture. The criteria used to select viable embryos that would under go 
further analysis was important as we wanted to ensure that all viable embryos selected 
would have a high chance of growing to the blastocyst stage and undergo normal 
development. Thus, any embryos that showed any signs of unhealthy morphology on day 
0.5 were discarded. A total percentage of 86.6% of the embryos microinjected at the one 
cell stage successfully grew to the blastocyst stage, showing a good percentage of total 
embryos micromanipulated. We can thus confirm that the micromanipulation procedure 
and media used in these experiments were of high quality with minimal wastage of 
embryos.  
 
In the experiments designed to study the fate of the injected mitochondria, the following 
experimental findings confirm the successful transfer, detection and survival of the 
injected mitochondria.  
Firstly, to distinguish between the C57 and Balb mtDNA types, verifying the sequence 
differences at the COIII polymorphic site following the digestion with the PsyI enzyme 
clearly showed that the COIII site present at position 9348 was specific to the C57 
mtDNA and not in the BALB mtDNA. This was confirmed by the expected 276bp and 
275bp digestion products generated for the C57 mtDNA in the first round of PCR 






digestion products generated was of equal intensities to that of the undigested 551bp 
fragment. The restriction enzyme PsyI did not cleave the BALB mtDNA which resulted 
in the 551bp fragment remaining intact. Consequently, we confirmed the differentiation 
between the two mouse sub-species of C57 and Balb mice. Using this information, we 
were able to confirm that the experimental design did indeed distinguish between the two 
mtDNA’s in the heterogeneous embryos created. Furthermore, as the mtDNA used in this 
experiment is directly isolated form liver samples of their respective mice types, we were 
able to confirm that the mtDNA being isolated in all further experiments using embryos 
did in reality belong to the C57 or Balb mice types.  
 
 
In the comparative study of the liver mitochondrial DNA samples isolated from the C57 
and Balb liver samples, to the day 0.5 embryos and blastocysts that were injected 
compared to the un-injected embryos, the findings presented here conclude a good initial 
comparison of the mtDNA from liver samples and embryos for the further studies 
conducted. This gave a good reference point on the fragments generated during PCR and 
digestion of the mtDNA’s in the further studies on the embryos. It also provides a good 
visual comparison of liver mtDNA and the early (day 0.5) and late (blastocyst) embryo 
development following micromanipulation.  
The embryos at Day 0.5 (injected versus not injected with Balb) and the blastocyst 
embryos (injected versus not injected with Balb), the second round PCR amplified the 
predicted two fragments of 384bp and 551bp. The intensity of the 384bp fragment was 






are merely remaining products of the first round PCR. There were also >1000bp 
fragments seen for all mtDNA samples studied. These were unexpected bands and could 
merely be a result of the expected contamination that would arise from dealing with 
minute quantities of DNA isolation and amplification. When comparing all embryo 
results obtained, the >1000bp fragments were seen in only some of the results and not a 
common result seem for all samples. This is clearly seen in figure 37 and 39 where the 
first round, and second round PCR products of mtDNA from liver samples and embryos 
at various stages did not produce any contamination resulting in the >1000bp fragment 
prior to and following digestion.  This further confirms that the >1000bp fragments seen 
in figure 35 could be merely products of contamination seen only in certain results. The 
results shown in figure 35 are initial experiments and are not the only core results 
showing the fate of the injected mitochondria. Future studies could include a similar 
experiment to confirm weather or not the >1000bp fragment is due to contamination or an 
issue of primer specificity. 
In the second round, PCR products were digested over night with the PsyI enzyme, the 
C57 mtDNA liver sample produced two predicted fragments at 108bp and 276/275 bp. 
These were precisely the cleavage products of the 384bp fragment that would be 
generated by the PsyI enzyme. The 108bp fragments were of weaker intensities in 
comparison to the 276/275 bp fragment as they are of a smaller base pair. In comparison, 
in the BALB liver mtDNA sample, the 384bp and 551bp fragment remained intact with 
the 384bp fragment showing a weaker intensity. The 551bp fragments seen were visually 
stronger than the 384bp fragments as expected, however, further studies could decrease 






before the second PCR is conducted, would further fine tune the PCR methodology used 
here. These results confirmed the absence of the COIII polymorphic site in the BALB 
mtDNA. 
Day 0.5 embryos that were not subjected to microinjection with BALB liver mtDNA 
showed intact 108bp and 276/275 bp fragments prior to and after digestion showing no 
presence of any BALB mtDNA as would be expected. Thus the PCR products are 
representative of the embryos native C57 mtDNA. 
In comparison, embryos at day 0.5 that were injected with BALB mtDNA, four 
fragments were generated following digestion. 108bp, 276/275 bp, 384bp and 551bp 
fragments were seen. The intensity of the ~276bp fragment was clearly stronger than the 
rest. The intensity of the 108bp fragments were of weakest intensity. This confirms that 
the microinjection of BALB Liver suspension into the embryo was successful and 
detectable. The BALB mtDNA that was injected remained intact after digestion, thus 
leaving the 384bp and 541bp fragments intact. The C57 mtDNA from the embryos was 
however digested into fragments of 108bp and 276/275 bp. There is a reasonable chance 
that due to any incomplete digestion of the C57 fragment, the resulting fragments may 
include the incompletely digested 384bp fragment. This would increase the intensity of 
the BALB fragments of digestion at the 384bp length. 
Single blastocyst embryos that were not injected with BALB mitochondrial suspension at 
the one cell stage showed similar results to the day 0.5 control embryos showing the 
absence of any BALB mtDNA. However, the blastocysts that had been injected at the one 
cell stage showed the intact 384bp and 541 bp fragments confirming the presence of the 






BALB mtDNA into the embryos and furthermore, that the BALB mtDNA remained in 
the embryos after incubation to the blastocyst stage. The mitochondria from the BALB 
mice were therefore not eliminated from the embryos after the microinjection or during 
incubation to the blastocyst stage of development.  
 
From the concentration comparison study to estimate the concentration of the foreign 
Balb mtDNA that was injected, in relation to the native C57 mtDNA concentration, the 
results show a very rough visual comparison of the native C57 and the foreign BALB 
mtDNA concentrations in the various embryonic stages when compared to the C57 and 
Balb mtDNA isolated from liver samples at various concentrations. There are several 
reasons for not being able to conclude on any clear concentration ratios between the 
native and foreign mitochondria here. One of the reasons for the difficulty faced was 
dependent on the mice strains used here. In future studies, the use of Mus spretus mice 
could eliminate this problem as there would be no need for the digestion of products and 
in addition, primer designing could produce clear fragment length differences. Secondly, 
it was very difficult to inject the exact volume of mitochondria into embryos during 
micromanipulation as it was not possible to control or measure the exact amount of such 
a minute amount of suspension being injected into the embryos. Another disadvantage 
was that the need for nested PCR primers to successfully amplify the embryonic mtDNA 
prevents us from using a methodology such as real time PCR to analyze the DNA 
amplification. In addition, it has been reported that mtDNA copy numbers in mouse 
oocytes have a highly variable number of mtDNA molecules in individual oocytes, with 






the mouse origin contain different numbers of mtDNA molecules47, 48, and 49. Further 
studies could however attempt to provide a broader range of the C75 and Balb liver 
mtDNA markers that could then provide a fine tuning in the concentration range 
comparison. In addition, the number of exact cycles required to adequately amplify 
fragments per PCR reaction can also be refined once the different mice strains are made 
available. In our study, we resorted to a high number of cycles as our experimental design 
required additional digestion steps before we could successfully detect the successful 
introduction of foreign mitochondria.  
 
From the results on the concentration studies, first round PCR products showed a 
decreasing concentration of C57 mtDNA from liver samples was apparent for the 1ng 
C57 mtDNA, 100pg C57mtDNA, 70pg C57mtDNA and 7pg C57mtDNA. The intensities 
in the 551bp fragments were corresponding with the decreasing concentrations. There 
was however no amplification for the 700 pg C57 mtDNA in the first round PCR. This 
could have been a result of a technical error and was later confirmed when there was a 
fragment generated in the second round.   
The Balb mtDNA liver samples for the 1ng Balb mtDNA and 700pg Balb mtDNA 
generated the expected 551bp fragment. However, the intensities did not correspond with 
the decreasing concentrations with the 700pg concentration showing slightly higher 
551bp fragment intensities to that of the 1ng. This could have been due to a simple 
pipeting error as the tinniest of errors when dealing with such small concentrations could 
result in a different concentration. In addition, since the concentrations were estimated 






accurate and are merely a rough estimate in concentrations. The 7pg Balb mtDNA 
samples did not produce any fragments in both PCR rounds and following digestion. This 
could have been due to the very low concentration of DNA used. None the less, this 
confirms that the concentration was truly lower than the other concentrations. All 
embryonic stages resulted in an expected 551bp fragment for all stages. However, we did 
not set out to estimate the concentrations per embryo stage, as we are aware that 
embryonic mtDNA does not replicate with embryonic development and embryos at a 
single stage could contain different concentrations when compared. 
 
In the second round PCR products that had not been subjected to digestion, all C57 and 
BALB mtDNA liver samples were amplified. All samples showed fragments of 384bp of 
the second round and 551bp generated from the first round PCR. All samples showed a 
weaker 551bp fragment as would be expected as these were the products carried over 
from the first round and are expected to be of a weaker intensity. For the 7pg C57 
mtDNA in lane 7, there was a single PCR product of 384bp produced from the second 
round as there was no amplification in the second round. This confirmed the presence of 
the DNA. However, the generation of products in the second round only, could have been 
a result of the small concentration used. The DNA present in the first round may not have 
been sufficient to generate a band, but on further amplification in the second round PCR, 
the DNA amplified to a detectable level. This was not the case for the 7pg Balb mtDNA 
where no fragment was produced even after the second PCR. This could have been due to 






fragments, it was not possible to provide an accurate comparison in the concentrations as 
all fragments had only slight variations in intensities. 
 
 Following digestion of the second round PCR products, the C57 mtDNA from liver 
samples in lanes 3-7 were completely digested with the PsyI enzyme which generated the 
expected fragments of 276/275 bp and 108bp with the ~276bp fragments clearly stronger 
than the 108bp. The ~276bp fragment was theoretically presumed to be of a higher 
intensity as it was a fragment with a combination of the 276bp and 275bp following 
digestion. This confirmed that there was only the C57 mtDNA present as all DNA were 
completely digested. In lanes 7 and 8 the BALB Liver mtDNA were not cleaved and 
remained intact confirming the absence of the COIII polymorphic site in the Balb 
mtDNA. Using these C57 and Balb mtDNA samples, we can confirm that the C57 
mtDNA generates the 108bp and ~276/275 bp fragment while the Balb mtDNA showed 
the intact 551bp and 384bp fragments. However, when it came to comparing the 
intensities of the fragments corresponding to their concentrations, it would be difficult to 
provide a concentration comparison as all fragments appeared to be of very similar 
intensities. This is due to the fact that PCR amplification follows an exponential curve 
until it reaches saturation. Due to our need to perform nested PCR at such high cycles per 
reaction, we were not able to give a visual concentration comparison following the 
second round of PCR. 
 
All embryos at the various stages showed similar results after digestion. Four fragments 






fragment showing a very weak intensity. From the results on liver mtDNA I have shown 
that the C57 mtDNA generates the 108bp and ~276/275 bp fragment while the Balb 
mtDNA showed the intact 551bp and 384bp fragments. Using this, I was able to confirm 
that all embryos did indeed contain both C57 and Balb mtDNA’s. The intensities of the 
Balb foreign mtDNA can thus be compared to the intensity of the corresponding digested 
liver Balb mtDNA samples. Further studies are needed to fine tune this methodology to 
provide various increments of the liver Balb mtDNA as a marker for a more precise 
concentration range and more conclusive results.  None the less, we can conclude that the 
Balb mtDNA was present at all embryonic stages following the successful 
micromanipulation procedure. However, it must be noted that PCR products do not allow 
us to conclude that the foreign Balb mitochondria remained active at all embryonic 
stages. The native C57 mtDNA presence was confirmed by the 276/275 bp and 108bp 
fragments that were generated as a result of the PsyI enzyme cleaving the COIII 
polymorphic site present only in the C57 mtDNA. The concentrations of the native 
mitochondria in the embryonic stages cannot however be confirmed. Further studies 
could attempt to fill in the missing gaps here by providing a broader range of C57 liver 
mtDNA as it is known that mtDNA copy numbers in mouse oocytes have a highly 
variable number of mtDNA molecules in individual oocytes, with the average copy 
number being ~ 100 000 for mouse. This indicates that not all oocytes of the mouse 
origin contain the same number of mtDNA molecules47, 48, and 49. This could be one 
explanation for the difficulty faced in attempting to show a visual representation of the 
concentrations of the mtDNA present in the heterogeneous embryos. Furthermore, with 






was difficult to produce an accurate concentration ratio of the two mtDNA’s in the 
heterogeneous embryos. It would prove important to know the concentration ratios 
between the native and foreign mtDNA as there may be a threshold at which the 
therapeutic effects of the mtDNA that has been manipulated in vitro to correct certain 
mutations could start to manifest. This may prove valuable in further studies as we 
progress in our knowledge in mitochondrial medicine. 
 
 
In the study carried out to compare all embryo developmental stages following their 
micromanipulation starting at day 0.5, all embryos showed successful transfer of the 
BALB mtDNA at the various stages. In addition, the Balb mtDNA was not sequentially 
eliminated during the embryo development.  
Embryos at day 0.5, 2 cell stage, morula and blastocyst stages that were injected with 
BALB mitochondrial suspension at the one cell stage showed four fragments generated 
following digestion with the enzyme PsyI. A 108bp, 276/275 bp, 384bp and 551bp 
fragments were seen as expected. This confirms that the microinjection of BALB Liver 
suspension into the embryo was successful and detectable. The BALB mtDNA that was 
injected remained intact after digestion, thus leaving the 384bp and 551bp fragments 
intact. The C57 mtDNA from the embryos were clearly digested into the expected 
fragments of 108bp and 276/275 bp.  
This confirms the presence of the BALB mtDNA in the embryos at the various 
developmental stages. Furthermore, the BALB mtDNA remained in the embryos after 






therefore not eliminated from the embryos after the microinjection or during incubation 
to the blastocyst stage of development.  
Although the second round products for the C57 and Balb mtDNA are a 108bp and 
384bp fragment consecutively, it was highly difficult to directly quantify the respective 
fragments for a better view on the concentrations of the two mtDNA’s in this thesis. This 
was due to the fact that both C57 and Balb mtDNA amplify a 384bp fragment in the 
second round. The only differentiating phase would be seen after the digestion of these 
fragments. However, due to incomplete digestion that may be possible in some cases, it 
would be difficult to conclude that the resulting 108bp fragment was representative of the 
C57 mtDNA concentration, where as the 384bp fragments were only of the Balb mtDNA 
and not a combination of some of the C57 undigested fragments as well.  
I have however presented detailed methodology on how further studies could use this 
experimental design when the appropriate mice sub strains are available. In the case of 
using for example, Mus Spretus in further experiments, one could clearly distinguish 
between the two fragments as the PCR products would be of different lengths. In 
addition, due to the restrictions on mice strains for this project, I was unfortunately faced 
with the designing of primers that produced fragments that needed to be further digested 
to distinguish between he two mtDNA’s. This could be easily eliminated with the 
availability of appropriate mice strains. Future studies may be done to confirm whether 
the C57 and BALB mtDNA concentrations can in fact be measured and compared by 
including a direct comparison of the two mtDNA’s using semi quantitative methodology. 
This could include P32 labeling and phosphoimaging to allow for quantitation of each 






using for example Mus Spretus mice. This methodology was not provided here due to 
availability of the appropriate mice and equipment at the time and the time restrictions 
faced with following a delay caused by mice availability. I do not provide further studies 
in this thesis as our selection of mice types was already limited and did not have the 
advantage of studying two distant mice strains.  
Similar blastocyst embryos resulting for the experiments carried out in this project could 
in future studies be re-implant into pseudo-pregnant females. By doing so, heteroplasmic 
mice generated could be studied to help understand the peculiarities of abnormal mtDNA 
distribution and its effects on pre- and post-natal development.  
 
Mitochondrial membrane potential has been shown to be a key indicator in cellular 
viability61, 62. Further research using our data presented here could be conducted where 
ATP can be measured using similar methods as described by Van Blerkom et al 61, 62. By 
using the JC-1 mitochondrial probe which can be used to estimate changes in membrane 
potential (∆Ψm), heterogeneity between the membrane potential of individual 
mitochondria within a cell have been found in a mouse female germline cells61. 62. It 
would be interesting to see if in further studies, what the changes in mitochondrial 
activity in embryos are where the altered mitochondrial mutations are introduced. This 
would give an indication of the effects of the mitochondria that have been altered in vitro, 
prior to their introduction into pseudo pregnant females. Additionally, it would provide 
an alternative approach to measuring the mitochondrial activity, as experiments conduced 
by us with the Oroboros polarographic oxygraph (paar KG, Graz, Austria) as initial 






the equipment in measuring very low oxygen concentrations, as in the case of single 
embryos.  Studies to measure the ATP production could also help in confirming whether 
the mitochondria injected into the embryos remains active or not in the embryos through 
to the blastocyst stages. 
In this thesis, we can conclude that our studies provide detailed and reproducible 
methodology which serve as good initial steps for the production of appropriate mouse 
models in studying mitochondrial diseases in future studies. The foreign mitochondria 
injected into the embryos were not sequentially eliminated through the development to 
the blastocyst stages and was clearly detectable at all the stages of development. Detailed 
methodology on the differentiation and detection of the two mtDNA mouse strain has 
also been successfully shown here.  Future work can be continued to study the 
concentrations of both the mtDNA types used. This would increase our knowledge on 
any concentration changes of both mtDNA’s that may be seen during the development of 
the embryos to the blastocyst stages. This would prove valuable in understanding the 
abnormalities of the respiratory chain often manifested in different degrees of severity 
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7. Buffer Compositions: 
 
7.1 CZB Medium 
 
Stock solution 1 
Nacl                                4.76 g/100mls 
Kcl                                  0.36 g/100mls 
KH2PO4                          0.160g/100mls 
Sodium lactate                2.67mls/100mls 
Sodium pyruvate             0.0297mls/100mls 
EDTA (sodium salt)        0.0405g/100mls                      
Penicillin        106 iu/L    0.05g/100mls                          
Streptomycin                   0.1g/10mls 
 
Stock solution 2 
NaHCO3                         0.84g/10mls 
 
Stock solution 3 
MgSO4                           1.4208g/10mls 
 
Stock solution 4 
CaCl2.2H2O                   2.499g/10mls 
 
Stock solution 5 
L-glutamine                  0.1461g/10mls       




Quantity  (mls) Comments 
1 15    mls Dilute stock 1 into water prior to mixing 
left over stocks, to prevent cloudiness 
(~100mls). 
2 3.75 mls 
3                    0.15 mls Make up stocks 2-5, up to 125mls 
embryo H2O (final volume). 
4 0.15 mls 
5 1.5   mls 
 
Osmolality range for CZB medium: ~283-286 m Osm.  
0.005 g/ml BSA added to final CZB buffer                                                                    
                                                                                                 










7.3 Mitochondrial Integrity study Buffers 
Extraction Buffer A: 10mM HEPES pH 7.5, containing 200mM mannitol, 70mM 
sucrose and 1 mM EGTA. The buffer was diluted five-fold with water and stored at 4°C. 
 
Extraction Buffer B: 20mM MOPS pH 7.5 containing 110 mM KCL and 1 mM EGTA. 
The working solution was prepared by a five-fold dilution and stored at 4°C. 
 
Storage Buffer: 10M HEPES pH 7.4 containing 250 mM sucrose, 1mM ATP, 0.08 mM 
ADP, 5mM sodium succinate, 2mM K2HPO4 and 1 mM DTT. The working solution was 
prepared by a five-fold dilution with water and stored at 4°C 
 
JC-1 Stain: A 25µg vial was diluted with 25mls of dry DMSO to give a working 
solution of 1mg/ml. The solution was stored at -20°C at this concentration. For assaying, 
a further five-fold dilution with dry DMSO was made. 
 
JC-1 Buffer: 20mM MOPS pH 7.5 containing 110 mM KCL, 10 mM ATP, 10 mM 
Mgcl2, 10 mM Sodium succinate and 1 mM EGTA. A five-fold dilution of the buffer was 
made and stored at 4°C before use. 
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